

Atty. Docket #: 199at07.us

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INTERNATIONAL APPL. NO.: PCT/EP00/04972 :

INTERNATIONAL FILING DATE: -MAY 31, 2000- :

APPLICANT: KLAUS REHFELDT ET AL :

SERIAL NO: (To be assigned) :

ART UNIT:

FILED: -HEREWITH- :

EXAMINER:

FOR: NOVEL ANTIMYCOTICS AND :
FUNGICIDES, PROCESSES :
FOR THEIR PREPARATION, AND THEIR USE :

Commissioner for Patents
Box PCT
Washington, D.C. 20231

"Express Mail" No.: ET284672026

Date: -JANUARY 03, 2002-

I hereby certify that this paper, along with any other paper or fee referred to in this paper as being transmitted herewith, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, on the date indicated above, addressed to Box PCT, Commissioner for Patents, Washington, D.C. 20231

-Barbara J. Miller-
(Typed or printed name of mailing paper or fee)

Barbara J. Miller
(Signature of person mailing paper)

**TRANSMITTAL OF APPLICATION PAPERS
TO U.S. DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. §371
(37 CFR 1.494 OR 1.495)**

This Transmittal Letter is based upon PTO Form 1390 (as revised in May, 1993).

The above-identified applicant(s) (jointly with their assignee) have filed an International Application under the P.C.T. and hereby submit(s) to the United States Designated/Elected Office (DO/EO/US) the following items and other information.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. §371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. §371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay.
4. ☒ A proper Demand for International Preliminary Examination (IPE) was made to the appropriate Authority (IPEA) within the time period required.
5. ☒ A copy of the International Application as filed (35 U.S.C. §371(c)(2)) --
 - a. ☒ is transmitted herewith (required when not transmitted by International Bureau).
 - b. ☐ has been transmitted by the International Bureau. See WIPO Publication WO 01/02587.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A (verified) translation of the International Application into the English language is enclosed ~~with~~ Nine Sheets of Drawings ~~and~~ Seven (7) Sheets of Sequence Listings.
7. ☐ Amendments to the (specification and) claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
 - e. ☐ will be submitted with the appropriate surcharge.
8. ☐ A translation of the amendments to the claims (and/or the specification) under PCT Article 19 (35 U.S.C. §371(c)(3)) is enclosed or will be submitted with the appropriate surcharge.

International Application No. PCT/EP00/04972

9. ☒ An oath or declaration/power of attorney of the inventor(s) (35 U.S.C. §371[c][4]) will follow.
[] and is attached to the translation of (or a copy of) the International Application.
[] and is attached to the substitute specification.

10. [] A translation of at least the Annexes to the IPE Report under PCT Article 36 (35 U.S.C. §371[c][5]) is enclosed.

Items 11. to 16. below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98 is enclosed.
12. ☒ An Assignment for recording and a separate cover sheet in compliance with 37 CFR 3.28 and 3.31 will follow.
13. ☒ A FIRST preliminary amendment is enclosed.
A SECOND or SUBSEQUENT preliminary amendment is enclosed.
14. [] A substitute specification (including claims, abstract, drawing) is enclosed.
15. [] A change of power of attorney and/or address letter is enclosed.
16. ☒ Other items of information:

- ☒ This application is being filed pursuant to 37 CFR 1.494(c) or 1.495(c), and any missing parts will be filed before expiration of--

[] 22 months from the priority date under 37 CFR 1.494(c), or

☒ 32 months from the priority date under 37 CFR 1.495(c).

- ☒ The undersigned attorney is authorized by the International applicant and by the inventors to enter the National Phase pursuant to 37 CFR 1.494(c) or 1.495(c).

The following additional information relates to the International Application:

10/01/99 107019963

JG13 Rec'd PCT/PTO 03 JAN 2002

International Application No. PCT/EP00/04972

199at07.us

- ☒ Receiving Office: EPO
- ☒ IPEA (if filing under 37 CFR 1.495): EPO
- ☒ Priority Claim(s) (35 USC §§ 119, 365):
GERMAN Appln. 199 30 959.0 filed -July 05, 1999-.
- ☒ A copy of the International Search Report is
 - ☐ enclosed.
 - ☒ attached to the copy of the International Application in German and English Translation.
- ☒ A copy of the Receiving Office Request Form is enclosed.
- ☒ Form PCT/IB/306 (3) pages
- ☒ Form PCT/IB/308 (1) sheet
- ☒ Form DSMZ-BP/9 & BP/4 Deposit and Viability Reports from the IDA (4) pages
- ☒ Seven (7) Sheets of Sequence Listings

The fee calculation is set forth on the next page of this Transmittal Letter.

10/019963

JC13 Rec'd PCT/PTO 03 JAN 2002

199at07.us

International Application No. PCT/EP00/04972

FEE CALCULATION SHEET

☒ A check in payment of the filing fee, calculated as follows, is attached (37 CFR 1.492).

Basic Fee..... \$ 890.00

Total Number of claims in
excess of (20) times \$18..X..7..... 126.00

Number of independent claims
in excess of (3) times \$84 252.00

Fee for multiple dependent
claims \$280..... -0-

TOTAL FILING FEE... \$ 1,268.00

Kindly send us the official filing receipt.

The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Deposit Account No. 03-2775. This is a "general authorization" under 37 CFR 1.25(b), except that no automatic debit of the issue upon allowance is authorized. An additional copy of this page is attached.

Respectfully submitted,

By 

William E. McShane
Reg. No. 32,707
CONNOLLY BOVE LODGE & HUTZ LLP
1220 Market Street
P.O. Box 2207
Wilmington, Delaware 19899
Tel. (302) 658-9141

WEM/bjm
Enclosures
F:\docs\fori\40975 = F:\docs\patn\56657.doc

10/019963

JC13 Rec'd PCT/PTO 03 JAN 2002

199at07.us

8602*37

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: KLAUS REHFELDT, ET AL.: INT'L. APPLN.: PCT/EP00/04972
SERIAL NO.: (To be assigned) : ART UNIT: TBA
FILED: * HEREWITH * : EXAMINER: TBA
FOR: NOVEL ANTIMYCOTICS :
AND FUNGICIDES, PROCESSES :
FOR THEIR PREPARATION :
AND THEIR USE :

Commissioner for Patents
Box PCT
Washington, D.C. 20231


"Express Mail" No.: ET 284672026

Date: January 3, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, D.C. 20231.

Barbara J. Miller

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

PRELIMINARY AMENDMENT

Sir:

Prior to the determination of the filing fee and any action on the merits of the accompanying new patent application, kindly amend the application as follows:

In the Claims:

Please amend claims 3, 4, 6, 8, 10, 11, 12, and 14 - 26 as follows. The amended claims are shown in their final form below. An underline/bracket version of the amended claims is provided as Appendix A.

3. (Amended) A protein toxin as claimed in claim 1, which has an antimycotic and/or fungicidal action.

4. (Amended) A protein toxin as claimed in claim 1, with glucanase activity.

6. (Amended) Nucleic acid encoding a glucanase and/or a protein toxin as claimed in claim 1 with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.

8. (Amended) A nucleic acid as claimed in claim 6, which is a DNA with a nucleic acid sequence in accordance with **SEQ ID No 1** of base position 1 to 951 or **SEQ ID No 2** of base position 1 to 717, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.

10. (Amended) A nucleic acid as claimed in claim 8 which can be obtained from DSM 12864 and/or DSM 12865.

11. (Amended) A nucleic acid as claimed in claim 6, which is contained in a vector, preferably in an expression vector or in a vector which is effective in gene therapy.

12. (Amended) A process for the preparation of a nucleic acid as claimed in claim 6, wherein the nucleic acid is synthesized chemically or isolated from a gene library with the aid of a probe.

14. (Amended) A process for the preparation of a polypeptide as claimed in claim 13, wherein a nucleic acid is expressed in a suitable host cell, said nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from *Williopsis californica* and/or *Zygosaccharomyces bailii* with an amino acid sequence in accordance

199at07.us
8602*37

with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.

15. (Amended) An antibody against a polypeptide as claimed in claim 13.

16. (Amended) A process for the preparation of an antibody as claimed in claim 15, wherein a mammal is immunized with a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids and, if appropriate, the antibodies formed are isolated.

17. (Amended) A drug product comprising:

(i) a nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from *Williopsis californica* and/or *Zygosaccharomyces bailii* with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim;

(ii) a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and/or

(iii) an antibody against a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and, if appropriate, one or more pharmaceutically acceptable additives and/or adjuvants.

18. (Amended) A process for the preparation of a drug product as claimed in claim 17, for the treatment of mycoses such as superficial, cutaneous and subcutaneous dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably *Candida* mycoses, wherein said process comprises the step of combining said nucleic acid, said polypeptide and/or said antibody with said one or more pharmaceutically acceptable additives and/or adjuvants.

19. (Amended) A diagnostic comprising:

(i) a nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from *Williopsis californica* and/or *Zygosaccharomyces bailii* with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim;

(ii) a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and/or

(iii) an antibody against a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and, if appropriate, one or more suitable additives and/or adjuvants.

20. (Amended) A process for the preparation of a diagnostic according to claim 19, for diagnosing mycoses such as superficial, cutaneous and subcutaneous

dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably *Candida* mycoses, wherein said process comprises the step of combining said nucleic acid, said polypeptide and/or said antibody with a pharmaceutically acceptable carrier.

21. (Amended) An assay for identifying functional interactors comprising:

(i) a nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from *Williopsis californica* and/or *Zygosaccharomyces bailii* with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim;

(ii) a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and/or

(iii) an antibody against a polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids; and, if appropriate, one or more acceptable additives and/or adjuvants.

22. (Amended) A method of using a nucleic acid as claimed in claim 6, wherein said method comprises the step of incorporating said nucleic acid into an assay for identifying functional interactors.

23. (Amended) A method of using a nucleic acid as claimed in claim 6, for finding variants, which comprises the step of screening a gene library with the nucleic acid and isolating the variant which has been found.

24. (Amended) A method of using a polypeptide as claimed in claim 13, wherein said polypeptide is incorporated into a medium which is then combined with foods or animal feeds to identify and/or control harmful yeasts and/or fungi in said foods or animal feeds.

25. (Amended) A process for growing DSM 12864 and/or DSM 12865, which comprises the step of growing said DSM 12864 and/or DSM 12865 in synthetic B and/or BAVC medium.

26. (Amended) A method of using a nucleic acid as claimed in claim 6, comprising the step of incorporating said nucleic acid into a vector for the generation of transgenic plants or plant cells.

Please add new claim 27 as follows:

--27. (New) A method of using a polypeptide as claimed in claim 13, wherein said method comprises the step of incorporating said polypeptide into an assay for identifying functional interactors.--

REMARKS

In the present Preliminary Amendment, claims 3, 4, 6, 8, 10, 11, 12, and 14 - 26 have been amended. New claim 27 has been added. Each of the dependent claims, as

199at07.us
8602*37


amended, now depends on only one preceding claim. Therefore, no additional fee is required for multiple dependency.

Prompt and favorable action is solicited.

Respectfully submitted,

CONNOLLY BOVE LODGE & HUTZ LLP

By: _____



William E. McShane
Reg. No. 32,707
P. O. Box 2207
Wilmington, DE 19899
(302) 888-6248
Attorney for Applicants

WEM:bjm
Enclosure: Appendix A
::ODMA\MHODMA\CB,180283,1

Appendix A
Underline/Bracket Version of Amended Claims

3. (Amended) A protein toxin as claimed in [claims 1 and 2]claim 1, which has an antimycotic and/or fungicidal action.
4. (Amended) A protein toxin as claimed in [any of claims 1 to 3]claim 1, with glucanase activity.
6. (Amended) Nucleic acid encoding a glucanase and/or a protein toxin as claimed in [any of claims 1-5]claim 1 with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.
8. (Amended) A nucleic acid as claimed in [claim 6 or 7]claim 6, which is a DNA with a nucleic acid sequence in accordance with **SEQ ID No 1** of base position 1 to 951 or **SEQ ID No 2** of base position 1 to 717, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.
10. (Amended) A nucleic acid as claimed in [any of claims 8-9]claim 8, which can be obtained from DSM 12864 and/or DSM 12865.
11. (Amended) A nucleic acid as claimed in [any of claims 6-10]claim 6, which is contained in a vector, preferably in an expression vector or in a vector which is effective in gene therapy.
12. (Amended) A process for the preparation of a nucleic acid as claimed in [any of claims 6-10]claim 6, wherein the nucleic acid is synthesized chemically or isolated from a gene library with the aid of a probe.
14. (Amended) A process for the preparation of a polypeptide as claimed in [claims 1-5 and 13]claim 13, wherein a nucleic acid [as claimed in any of claims 6-11] is expressed in a suitable host cell, said nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from Williopsis californica and/or Zygosaccharomyces bailii with an amino acid sequence in accordance with SEQ ID No 1 or SEQ ID No 2 or a functional variant thereof, and portions thereof with at least 8 nucleotides, where SEQ ID No 1 or SEQ ID No 2 is part of the claim.
15. (Amended) An antibody against a polypeptide as claimed in [any of claims 1-5 and 13]claim 13.

16. (Amended) A process for the preparation of an antibody as claimed in claim 15, wherein a mammal is immunized with a polypeptide [as claimed in claim 7] with an amino acid sequence in accordance with SEQ ID No 1 or SEQ ID No 2 or a functional variant thereof, and portions thereof with at least 6 amino acids and, if appropriate, the antibodies formed are isolated.

17. (Amended) A drug product comprising [a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 and, if appropriate, pharmaceutically acceptable additives and/or adjuvants]:

(i) a nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from Williopsis californica and/or Zygosaccharomyces bailii with an amino acid sequence in accordance with SEQ ID No 1 or SEQ ID No 2 or a functional variant thereof, and portions thereof with at least 8 nucleotides, where SEQ ID No 1 or SEQ ID No 2 is part of the claim;

(ii) a polypeptide with an amino acid sequence in accordance with SEQ ID No 1 or SEQ ID No 2 or a functional variant thereof, and portions thereof with at least 6 amino acids; and/or

(iii) an antibody against a polypeptide with an amino acid sequence in accordance with SEQ ID No 1 or SEQ ID No 2 or a functional variant thereof, and portions thereof with at least 6 amino acids; and, if appropriate, one or more pharmaceutically acceptable additives and/or adjuvants.

18. (Amended) A process for the preparation of a drug product as claimed in claim 17, for the treatment of mycoses such as superficial, cutaneous and subcutaneous dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably Candida mycoses, wherein [a] said process comprises the step of combining said nucleic acid [as claimed in any of claims 6-10 or a], said polypeptide [as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 is/are]and/or said antibody [formulated together] with [a] said one or more pharmaceutically acceptable [additive]additives and/or [adjuvant]adjuvants.

19. (Amended) A diagnostic comprising [a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 and, if appropriate, suitable additives and/or adjuvants]:

(i) a nucleic acid encoding a glucanase and/or a protein toxin which can be obtained from Williopsis californica and/or Zygosaccharomyces bailii with an amino acid

thereof with at least 6 amino acids; and, if appropriate, one or more acceptable additives and/or adjuvants.

22. (Amended) [The use of]A method of using a nucleic acid as claimed in [any of claims 6-10 or of a polypeptide as claimed in any of claims 1-5 and 13]claim 6, wherein said method comprises the step of incorporating said nucleic acid into an assay for identifying functional interactors.

23. (Amended) [The use of]A method of using a nucleic acid as claimed in [any of claims 6-10]claim 6, for finding variants, which comprises the step of screening a gene library with the [abovementioned] nucleic acid and isolating the variant which has been found.

24. (Amended) [The use of]A method of using a polypeptide as claimed in [any of claims 1-5 and 13 for controlling] claim 13, wherein said polypeptide is incorporated into a medium which is then combined with foods or animal feeds to identify and/or control harmful yeasts [and]and/or fungi in said foods [and]or animal feeds.

25. (Amended) A process for growing DSM 12864 [and]and/or DSM 12865, which comprises the step of growing [them]said DSM 12864 and/or DSM 12865 in synthetic B and/or BAVC medium.

26. (Amended) [The use of the nucleic acids]A method of using a nucleic acid as claimed in [any of claims 6-11]claim 6, comprising the step of incorporating said nucleic acid into a vector for the generation of transgenic plants [and]or plant cells.

NOVEL ANTIMYCOTICS
AND FUNGICIDES,
PROCESSES
FOR THEIR PREPARATION,
AND THEIR USE

Klaus Rehfeldt
Simone Theisen
Frank Weiler
-and-
Manfred Schmitt


ENGLISH TRANSLATION
OF
INTERNATIONAL APPLICATION
-with-

Nine (9) Sheets of Drawings
-and-

Seven (7) Sequence Listing Sheets

PCT/EP00/04972 IFD: -May 31, 2000-

199at07.us (8602*37)

"Express Mail" mailing label
number ET284672026
Date of Deposit
-JANUARY 03, 2002-
I hereby certify that this paper or fee is
being deposited with the United States Postal
Service "Express Mail Post Office to
Addressee" service under 37CFR 1.10 on the
date indicated above and is addressed to Box
PCT, Commissioner for Patents,
Washington, D.C. 20231
-Barbara J. Miller-
(Typed or printed name of person mailing
paper or fee)

(Signature of person mailing paper or fee)

g/pst

WO 01/02587

PCT/EP00/04972

Novel antimycotics and fungicides, processes for their preparation, and their use

5 Description

The present invention relates to novel antimycotics and fungicides which can be obtained from yeast, processes for their preparation, and their use

- 10 Selective antimycotics are extremely important since fungal and/or yeast infections have increased enormously in recent years in humans, and also continue to result in undesired contamination in foods and animal feeds. Mycoses have particularly grave consequences in immunosuppressed patients whose cellular and humoral defense system must be kept at a
- 15 level which is not fully functional [Anaissie, 1992; Meunier *et al.*, 1992; Wingard, 1995]. Extremely endangered by mycoses are patients infected with *HIV-1* (AIDS), who very frequently die during a later stage of the disease from opportunistic infections by fungi and/or yeasts which are pathogenic for man [Levy, 1993]. The antimycotics which are currently
- 20 employed for the therapy of such infections (such as amphotericin B, fluconazole, itraconazole, ketoconazole) cause considerable side effects since they destroy the structural integrity of the eukaryotic cytoplasmic membrane and thus also damage the infected host organism [Hector, 1993]. Moreover, the application of conventional antimycotics has led within
- 25 only a short time to a rapid increase in fluconazole resistances which spread rapidly among the microorganisms which are pathogenic for man and constitute an ever increasing problem [Cameron *et al.*, 1993; Chavenet *et al.*, 1994; Maenza *et al.*, 1996; Pfaller *et al.*, 1994; Rex *et al.*, 1995; Troillet *et al.*, 1993]. It is therefore an important desire to develop
- 30 antimycotics which – like bacterial antibiotics – are distinguished by high selectivity and which attack, if possible, only fungi and yeasts which are pathogenic for man. Since, however, most of all cellular processes in higher organisms are governed by gene products which show a high degree in functional homology in eukaryots, the development of
- 35 “specifically antifungal antibiotics” has hitherto been unsuccessful [Kurz, 1998; Komiyama *et al.*, 1998].

A target of selective antimycotics are the β -1,3-D-glucans of the yeast cell wall which are indispensable for the mechanic and osmotic stability of the

cell, but do not occur in higher eukaryots and, constituting an "Achilles heel", might thus be exploited in the control of pathogenic yeasts [Roemer *et al.*, 1994]. Even though substances which selectively engage in the cell wall structure of yeasts and fungi are thus of great interest, no antibiotic-like inhibitors have been employed as yet for controlling mycoses. While bacterial antibiotic-producers were discovered as early as the beginning of the present century, similar effects in yeasts were only observed at the beginning of the 60's by identifying so-called killer yeasts [Bevan & Makower, 1963]: toxin-producing killer strains of the brewer's yeast *Saccharomyces cerevisiae* produce and secrete proteins termed "killer toxins" which destroy sensitive yeasts in a receptor-dependent process [Bussey, 1991; Tipper & Schmitt, 1991]. In *S. cerevisiae*, the ability of producing toxins is based on infections with reovirus-like double-stranded RNA viruses which stably and in high copy number persist in yeast cytoplasm without noticeably damaging the eukaryotic host cell [Tipper & Schmitt, 1991]. The three killer toxins of the yeast *S. cerevisiae* which are known to date (K1, K2, K28) are unglycosylated α/β -heterodimers which are translated by the infected cell as highly molecular preprotoxins and which are processed during the intracellular secretion pathway by complex modification to give the bioactive killer proteins [Hanes *et al.*, 1986; Dignard *et al.*, 1991; Schmitt & Tipper, 1995]. The toxic effect of the *S. cerevisiae* toxins is based either on a destruction of the membrane integrity (toxins K1, K2) or (as in the case of killer toxin K28) on arresting the cell cycle with a direct inhibition of DNA synthesis [Bussey, 1991; Schmitt & Compain, 1995; Schmitt *et al.*, 1996]. Even though killer toxins of the classes K1, K2 and K28 differ markedly from each other with regard to their modes of action and their physicochemical properties, they share the characteristics of having narrow spectra of action and of predominantly destroying sensitive yeasts of closely related species. This limited spectrum of action is based on the fact that the brewer's yeast killer toxins which have been characterized so far must interact with different receptor populations at the yeast cell wall and cytoplasmic membrane levels in order to be able to destroy sensitive target cells. The primary toxin receptors of the yeast cell wall are either highly branched β -1,6-D-glucans or the outer mannotriose side chains of a cell wall mannoprotein [Bussey, 1991; Schmitt & Radler 1987, 1988].

Apart from the viral protein toxins of the yeast *S. cerevisiae*, *Hanseniaspora uvarum*, *Zygosaccharomyces bailii* and *Ustilago maydis*, killer strains have

also been described in the genera *Debaryomyces*, *Hansenula*, *Cryptococcus*, *Rhodotorula*, *Trichosporon*, *Pichia*, *Kluyveromyces*, *Torulopsis* and *Williopsis* [McCracken *et al.*, 1994; Park *et al.*, 1996; Schmitt & Neuhausen, 1994; Walker *et al.*, 1995]. In these yeasts, however, the genetic base of the killer phenomenon is not viral genomes, but either linear dsDNA plasmids or chromosomal yeast genes [Schründer *et al.*, 1994].

Intensive studies into the molecular biology of various toxin-producing "killer yeasts" have shown that the secretion of toxic proteins ('killer toxins') is widespread in yeasts and constitutes a potential in the development of selective antimycotics which should not be underestimated [Walker *et al.*, 1995; Hodgson *et al.*, 1995; Polonelli *et al.*, 1986; Schmitt & Neuhausen, 1994; Neuhausen & Schmitt, 1996; Schmitt *et al.*, 1997], but it has hitherto been impossible to provide such protein toxins.

It is therefore an object of the present invention to provide suitable antimycotic or fungicidal protein toxins for controlling yeast and/or fungi which are pathogenic for man and plants.

Surprisingly, the killer toxin WICALTIN (also protein toxin) from the wild-type yeast *Williopsis californica* strain 3/57 (DSM 12865), which is produced and secreted in a highly efficient fashion, and the virus-encoded ZYGOCIN (also protein toxin) from the yeast *Zygosaccharomyces bailii* (DSM 12864) prove to be particularly suitable for controlling yeast and/or fungi which are pathogenic for man and plants. Moreover, fungi and harmful yeasts which are a hazard in the food and animal feed sector can also be destroyed. Both protein toxins therefore have the potential of being employed as antimycotics and/or fungicides for controlling yeast and/or fungal infections, in particular mycoses. These indications are verified in the present invention by studies into the mode of action. The toxin genes are cloned and sequenced in a suitable manner for the purposes of the present invention, thus establishing a process for the recombinant production and overexpression of WICALTIN and ZYGOCIN in culture.

A subject matter of the invention therefore relates to protein toxins which can be obtained from *Williopsis californica*, especially preferably strain DSM 12865, and *Zygosaccharomyces bailii*, especially preferably strain DSM 12864. Both strains were deposited on 9th June 1999 at the DSMZ-

Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, in 38124 Braunschweig, Mascheroder Weg 1b in compliance with the provisions of the Budapest Treaty (www.dsmz.de).

5 For the purposes of the present invention, it is in particular DSM 12864 and
DSM 12865 which secrete biologically potent protein toxins which, owing to
their broad spectrum of action (see Example 4 and 7), also destroy a large
10 number of yeasts and fungi which are pathogenic for man and plants. The
invention thus also relates to selective antimycotics or fungicides in the
sense of the protein toxins – and the polypeptides hereinbelow according to
the invention and their encoding nucleic acids according to the invention, in
particular in the functional unit of a toxin gene – being potential
biopharmaceuticals which, owing to their specific, receptor-medium
15 production, exclusively destroy yeasts and/or fungi and which are thus
entirely harmless to higher eukaryots - and thus also to humans and
mammalian cells – and to plants, preferably crop plants [cf. Pfeiffer *et al.*,
1988].

20 The following yeasts and/or fungi which are apathogenic or pathogenic for
man and plants can be destroyed selectively:

Zygocin-sensitive yeast species: *Saccharomyces cerevisiae*, *Candida*
albicans, *Candida krusei*, *Candida glabrata*, *Candida vinii*, *Hanseniaspora*
uvarum, *Kluyveromyces marxianus*, *Methschnikowia pulcherrima*, *Ustilago*
maydis, *Debaryomyces hansenii*, *Pichia anomala*, *Pichia jadinii*, *Pichia*
25 *membranefaciens*, *Yarrowia lipolytica* and *Zygosaccharomyces rouxii*.

Wicaltin-sensitive yeast species: *Candida albicans*, *Candida glabrata*,
Candida tropicalis, *Debaryomyces hansenii*, *Kluyveromyces lactis*,
Metschnikowia pulcherrima, *Pichia anomala*, *Pichia jadinii*, *Saccharomyces*
cerevisiae, *Sporthrix spec.*, *Torulaspora delbrueckii*, *Torulaspora*
30 *pretoriensis*, *Yarrowia lipolytica* and *Zygosaccharomyces bailii*.

The particularly high activity of the wicaltin-producing yeast strain DSM
12865 is probably based on its pronounced secretory efficiency, which is
markedly more pronounced in comparison with other strains of the same
35 yeast species. The 'killer' property of the zygocin-producing yeast strain
DSM 12864 is based on infection with toxin-encoding double-strand RNA
viruses (Mz_b-dsRNA) which stably persist in the cytoplasm in high copy
number and which enable the yeast in question (strain DSM 12864) to
produce and secrete zygocin [cf. Schmitt & Neuhausen, 1994]. Other

strains of the same species show no toxic production since they do not harbor toxin-encoding dsRNA viruses in the cytoplasm and are thus to be classified phenotypically as 'non-killer'.

- 5 Another subject matter of the present invention is therefore nucleic acids encoding for a protein toxin – with an amino acid sequence in accordance with **SEQ ID No 1 and No 2** and a glucanase activity – or a functional variant thereof, and sections thereof with at least 8 nucleotides, preferably with at least 15 or 20 nucleotides, in particular with at least 100 nucleotides, especially with at least 300 nucleotides (subsequently termed "nucleic acid(s) according to the invention").

15 The complete nucleic acids encoding for protein toxins which, after intracellular processing and secretion, have a size of 309 amino acids and a molecular mass of 34 kDa (**SEQ ID No 1**) or of 99 amino acids and a molecular mass of 10 kDa (**SEQ ID No 2**). Expression of the nucleic acid in accordance with **SEQ ID No 1** in the yeast *S. cerevisiae* results in a recombinant WICALTIN, which is secreted into the culture supernatant of the yeast as a glycosylated protein with significant β -1,3-D-glucanase activity [cf. Example 10]. Further experiments in accordance with the present invention confirm that the nucleic acids according to the invention are nucleic acids which in the case of **SEQ ID No 1**, encode a protein toxin with glucanase activity and, in the case of **SEQ ID No 2**, a protein toxin which is probably O-glycosylated *in vivo* and is termed ZYGOCIN. The nucleic acids according to the invention can be obtained from DSM 12865 (**SEQ ID No 1**) and DSM 12864 (**SEQ ID No 2**).

30 In a preferred embodiment, the nucleic acids according to the invention are DNA or RNA, preferably a double-stranded DNA, and in particular a DNA with a nucleic acid sequence in accordance with **SEQ ID No 1** from position 1 to position 947 and in accordance with **SEQ ID No 2** from position 1 to position 713. In accordance with the present invention, the two positions determine the start and the end of the encoding region, i.e. in each case the first and last amino acid of the reading frame in question.

35 The term "functional variant" is to be understood as meaning in accordance with the present invention a nucleic acid which are functionally related to the nucleic acids according to the invention. Examples of related nucleic acids are nucleic acids from different yeast cells or strains and cultures or

allelic variants. The present invention also encompasses variants of nucleic acids which can be derived from a variety of yeasts/yeast strains or other pathogens such as dermatophytes and molds (in accordance with the DHS system).

5

The term "variants" in accordance with the present invention is furthermore to be understood as meaning nucleic acids which exhibit a homology, in particular a sequence identity, of approx. 60%, preferably of approx. 75%, in particular of approx. 90% and especially of approx. 95%.

10

The sections of the nucleic acid according to the invention can be used, for example, for generating individual epitopes, as probes for identifying further functional variants, or as antisense nucleic acids. For example, a nucleic acid of at least approx. 8 nucleotides is suitable as antisense nucleic acid, a nucleic acid of at least approx. 15 nucleotides as primer in the PCR method, a nucleic acid of at least approx. 20 nucleotides for the identification of further variants, and a nucleic acid of at least approx. 100 nucleotides as probe.

15

In a further preferred embodiment, the nucleic acid according to the invention contains one or more noncoding sequences and/or a poly(A)-sequence, one or more Kex2p endopeptidase recognition sequences (required for intracellular proprotein processing), and one or more potential N-glycosylation sites. The noncoding sequences are regulatory sequences such as promoter or enhancer sequences for the controlled expression of the coding toxin gene containing the nucleic acids according to the invention.

20

25

In a further embodiment, the nucleic acid according to the invention is therefore contained in a vector, preferably in an expression vector or in a vector which is effective in gene therapy.

30

Examples of expression vectors can be, in the case of the nucleic acid in accordance with **SEQ ID No 2**, prokaryotic and/or eukaryotic expression vectors, and, in the case of the nucleic acid in accordance with **SEQ ID No 1**, exclusively eukaryotic expression vectors. Expression of the toxin-encoding nucleic acid in accordance with **SEQ ID No 1** in *Escherichia coli* is not possible since the respective, heterologously expressed protein toxin is toxic to the bacterial cell. Cloning of the WICALTIN-encoding nucleic acid in accordance with **SEQ ID No 1** in *E. coli* is only possible with plasmids

35

which do not carry a promoter (for example with the aid of derivatives of plasmid pBR322). An example of a prokaryotic vector which allows heterologous expression of the ZYGOCIN-encoding nucleic acid in accordance with **SEQ ID No 2** is the commercially available vector pGEX-4T-1, which allows a glutathione S transferase/ZYGOCIN fusion protein to be expressed in *E. coli*. A further vector for the expression of ZYGOCIN in *E. coli* is, for example, the T7 expression vector pGM10 (Martin, 1996), which encodes an N-terminal Met-Ala-His6 tag which allows an advantageous purification of the expressed protein through an Ni^{2+} -NTA column. Examples of suitable eukaryotic expression vectors for the expression in *Saccharomyces cerevisiae* are the vectors p426Met25 or p426GAL1 (Mumberg et al. (1994) Nucl. Acids Res., 22, 5767), for the expression in insect cells baculovirus vectors such as those disclosed in EP-B1-0127839 or EP-B1-0549721, and for expression in mammalian cells SV40 vectors, which are freely available.

In general, the expression vectors also contain regulatory sequences which are suitable for the host cell, such as, for example, the trp promoter for expression in *E. coli* (see, for example, EP-B1-0154133), the ADH-2 promoter for expression in yeasts (Russel et al. (1983), J. Biol. Chem. 258, 2674), the baculovirus polyhedrin promoter for expression in insect cells (see, for example, EP-B1-0127839), or the early SV40 promoter, or LTR promoters, for example those of MMTV (Mouse Mammary Tumor Virus; Lee et al. (1981) Nature, 214, 228).

Examples of vectors which are effective in gene therapy are viral vectors, preferably adenoviral vectors, in particular replication-deficient adenoviral vectors, or adeno-associated viral vectors, for example an adeno-associated viral vector which consists exclusively of two inserted terminal repetitive sequences (ITRs).

Suitable adenoviral vectors are described, for example, by McGrory, W.J. et al. (1988) Virol. 163, 614; Gluzman, Y. et al. (1982) in "Eukaryotic Viral Vectors" (Gluzman, Y. ed.) 187, Cold Spring Harbor Press, Cold Spring Harbor, New York; Chroboczek, J. et al. (1992) Virol. 186, 280; Karlsson, S. et al. (1986) EMBO J.. 5, 2377 or WO95/00655.

Examples of suitable adeno-associated viral vectors are described by Muzyczka, N. (1992) Curr. Top. Microbiol. Immunol. 158, 97; WO95/23867;

Samulski, R.J. (1989) J. Virol, 63, 3822; WO95/23867; Chiorini, J.A. et al. (1995) Human Gene Therapy 6, 1531 or Kotin, R.M. (1994) Human Gene Therapy 5, 793.

- 5 Vectors which are effective in gene therapy can also be obtained by complexing the nucleic acid according to the invention with liposomes. Suitable lipid mixtures for this purpose are those described by Felgner, P.L. et al. (1987) Proc. Natl. Acad. Sci, USA 84, 7413; Behr, J.P. et al. (1989) Proc. Natl. Acad. Sci. USA 86, 6982; Felgner, J.H. et al. (1994) J. Biol.
- 10 Chem. 269, 2550 or Gao, X. & Huang, L. (1991) Biochim. Biophys. Acta 1189, 195. When producing the liposomes, the DNA is bound ionically on the liposomal surface in such a ratio that a positive nett charge remains and the DNA is complexed completely by the liposomes.

- 15 In a further embodiment, the nucleic acids according to the invention are therefore contained in a vector, preferably in an expression vector for the generation of transgenic plants. Since the above-described killer toxins WICALTIN and ZYGOCIN have a broad spectrum of action and also destroy yeasts and fungi which are pathogenic for plants, it is possible to
- 20 provide transgenic plants which behave in a resistant fashion for example to an infection with the pathogen *Ustilago maydis*, which is pathogenic for maize. Similar experiments have already been carried out on tobacco plants which, owing to heterologous expression of the *U. maydis* killer toxin KP4, which in nature is encoded by a virus, were capable of secreting the
- 25 protein toxin in question and thus built up a specific protection from infection with certain phytopathogenic *U. maydis* strains (Park et al., 1996; Kinal et al., 1995; Bevan, 1984). Starting from commercially available transformation systems which are based on modified derivatives of the natural *Agrobacterium tumefaciens* Ti plasmid, the nucleic acids according
- 30 to the invention, which are also represented in the toxin genes *WCT* and *ZBT*, can be cloned into so-called bidirectional pBI vectors (CLONTECH) and employed for the generation of transgenic plants. To this end, the respective toxin genes *WCT* and *ZBT* are placed under the transcriptional control of the strong cauliflower mosaic virus promoter (CaMV-P). The
- 35 more detailed construction of the vectors to be constructed is shown schematically in Example 9.

For example, the nucleic acids according to the invention can be synthesized chemically, for example following the phosphotriester method,

with reference to the sequences disclosed in **SEQ ID No 1 and No 2** or with reference to the peptide sequences disclosed in **SEQ ID No 1 and No 2**, taking into consideration the genetic code (see, for example, Uhlman, E. & Peyman, A. (1990) Chemical Reviews, 90, 543, No. 4). Another possibility of obtaining the nucleic acid according to the invention is the isolation of a suitable gene bank with the aid of a suitable probe (see, for example, Sambrook, J. et al. (1989) Molecular Cloning. A laboratory manual. 2nd Edition, Cold Spring Harbor, New York). Suitable probes are, for example, single-stranded DNA fragments with a length of approx. 100 to 1000 nucleotides, preferably with a length of approx. 200 to 500 nucleotides, in particular with a length of approx. 300 to 400 nucleotides, whose sequence can be deduced from the nucleic acid sequence in accordance with **SEQ ID No 1 and No 2**.

Another subject matter of the present invention are the polypeptides as such with an amino acid sequence in accordance with **SEQ ID No 1 and No 2** or a functional variant thereof, and portions thereof with at least six amino acids, preferably with at least 12 amino acids, in particular with at least 65 amino acids, and especially with 309 amino acids (**SEQ ID No 1**) and with 99 amino acids (**SEQ ID No 2**) (hereinbelow "polypeptide(s)" according to the invention"). For example, a polypeptide which is approximately 6-12, preferably approx. 8 amino acids in length, may contain an epitope which, after coupling to a support, serves for the production of specific polyclonal or monoclonal antibodies (see, in this context for example US 5,656,435). Polypeptides with a length of at least approx. 65 amino acids can also serve directly for the preparation of polyclonal or monoclonal antibodies, without support.

The term "functional variants" for the purposes of the present invention is to be understood as meaning polypeptides which are functionally related to the peptide according to the invention, i.e. which exhibit glucanase activity. Variants are also understood as meaning allelic variants or polypeptides which may be derived from various yeasts/yeast strains or other infective agents such as dermatophytes, molds (in accordance with the DHS system).

In the wider sense, they are also to be understood as meaning polypeptides which have a sequence homology, in particular a sequence identity of approx. 70%, preferably of approx. 80%, in particular of approx.

In particular the abovementioned portions of the polypeptide can also be synthesized with the aid of traditional peptide synthesis (Merrifield technique). They are particularly suitable for obtaining antisera, with the aid of which suitable gene expression libraries can be screened in order to

arrive at further functional variants of the polypeptide according to the invention.

5 A further subject matter of the present invention thus relates to a process for the preparation of a polypeptide according to the invention, wherein a nucleic acid according to the invention is expressed in a suitable host cell and, if appropriate, isolated.

10 Very especially preferred is the fission yeast *Schizosaccharomyces pombe*, since this yeast is WICALTIN- and ZYGOCIN-resistant by nature and has already been repeatedly employed successfully for the heterologous expression of foreign proteins [Giga-Hama & Kumagai (1997), in "Foreign Gene Expression in Fission Yeast: *Schizosaccharomyces pombe*", Springer Verlag]. As exemplified in Example 11, the toxin-encoding nucleic acids in accordance with **SEQ ID No 1** and **SEQ ID No 2** can be cloned, for example, into the *S. pombe* vector pREP1 [Maundrell (1990), J. Biol. Chem. 265:10857-10864], in which they are under the transcriptional control of the thiamine-regulated *nmt1* promoter of the fission yeast [*nmt* = 'no message with thiamine']. Yeasts which are transformed with such a vector express the foreign gene in question as a function of the respective thiamine concentration in the culture medium of the yeast. If desired, this allows the yeast growth phase to be separated in time from the phase during which the foreign protein is produced, so that in principle it is also possible to express proteins which are toxic to the yeast. To allow simultaneous secretion and thus a considerably easier purification of the toxins WICALTIN and ZYGOCIN, which are expressed heterologously in *S. pombe*, we already have constructed an expression/secretion vector [Vector pTZ α/γ ; see Example 11] which contains secretion and processing signals of the viral K28 preprotoxin gene [Schmitt & Tipper, 1995] and thus allows effective secretion of the respective foreign protein which is arranged downstream in-frame.

35 Another subject matter of the present invention also relates to antibodies which specifically react with the polypeptide according to the invention, it being possible for the abovementioned portions of the polypeptide either to be immunogenic themselves or to be made immunogenic, or improved in their immunogenicity by coupling to suitable carriers such as, for example, bovine serum albumin.

The antibodies are either polyclonal or monoclonal. The preparation, which also constitutes a subject matter of the present invention, is carried out for example by generally customary methods by immunizing a mammal, for example a rabbit, with the polypeptide according to the invention or the

5 abovementioned portions thereof, if appropriate in the presence of, for example, Freund's adjuvant and/or aluminum hydroxide gels (see, for example, Diamond, B.A. et al. (1981) The New England Journal of Medicine, 1344). The polyclonal antibodies formed in the animal owing to an immunological reaction can subsequently readily be isolated from the

10 blood by generally customary methods and purified, for example by column chromatography. It is preferred to subject the antibodies to an affinity purification, where for example the antigen in question (ZYGOCIN or WICALTIN) is coupled covalently with a CnBr-activated Sepharose matrix which is freely available and employed for purifying the antibodies, which

15 are in each case toxin-specific.

Monoclonal antibodies can be prepared for example by the known methods of Winter & Milstein (Winter, G. & Milstein, C. (1991) Nature, 349, 293).

20 Another subject matter of the present invention is a drug product which comprises the nucleic acids according to the invention or the polypeptides according to the invention (individually or in combination) and, if appropriate, suitable additives or adjuvants, and a process for the preparation of a drug product for treating mycoses such as superficial,

25 cutaneous and subcutaneously dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably Candida mycoses, wherein a nucleic acid according to the invention or a polypeptide according to the invention is formulated together with pharmaceutically acceptable additives and/or adjuvants.

30 Example 12 exemplifies that the toxin WICALTIN, which is produced by the strain DSM 12865 and purified, even has a markedly more potent toxicity to yeasts than the topical antimycotics clotrimazole and miconazole which were tested for comparison reasons and are frequently employed in the

35 therapy of mycoses.

The invention thus also relates to a drug product in the above sense, comprising an antimycotic or a protein toxin obtainable from DSM 12864

and/or DSM 12865 and/or antimycotically active polypeptides according to the invention.

5 Sutable for use in human gene therapy is especially a drug product which comprises the nucleic acid according to the invention in naked form or in the form of one of the above-described vectors which are effective in gene therapy or in the form of complexes with liposomes.

10 Examples of suitable additives and/or adjuvants are a physiological saline, stabilizers, proteinase inhibitors, nuclease inhibitors and the like.

15 Another subject matter of the present invention is also a diagnostic comprising a nucleic acid according to the invention, a polypeptide according to the invention or an antibody according to the invention and, if appropriate, suitable additives and/or adjuvants, and a process for the preparation of a diagnostic for diagnosing mycoses such as superficial, cutaneous and subcutaneous dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably Candida mycoses, wherein a nucleic acid according to the invention, a polypeptide
20 according to the invention or antibodies according to the invention are combined with suitable additives and/or adjuvants.

For example, a diagnostic based on the polymerase chain reaction (PCR diagnostic for example in accordance with EP-0200362) or on a Northern
25 and/or Southern Blot, as described in greater detail in Example 13, can be prepared in accordance with the present invention with the aid of the nucleic acid according to the invention. These tests are based on the specific hybridization of the nucleic acid according to the invention with the complementary strand, conventionally the corresponding mRNA. The
30 nucleic acid according to the invention can also be modified, as described, for example, in EP0063879. Preferably, a DNA fragment according to the invention is labeled by generally known methods by means of suitable reagents, for example radiolabeled with α -P³²-dATP or provided with a non-radioactive biotin label, and incubated with isolated RNA which has
35 preferably been bound to suitable membranes, for example of cellulose or nylon. In addition, it is advantageous to separate the isolated RNA prior to hybridization and binding to a membrane according to size, for example by means of agarose gel electrophoresis. If the amount of test RNA from each

tissue sample is identical, the amount of mRNA which has been labeled specifically by the probe can thus be determined.

5 Another diagnostic comprises the polypeptide according to the invention or the immunogenic portions thereof which have been described above in greater detail. The polypeptide or portions thereof, which are preferably bound to a solid phase, for example of nitrocellulose or nylon, can be contacted in vitro for example with the body fluid to be examined, such as blood, in order to be able to react with, for example, antibodies. The antibody/peptide complex can subsequently be detected, for example with the aid of labeled anti-human-IgG or anti-human-IgM antibodies. The label is, for example, an enzyme such as peroxidase which catalyzes a color reaction. Presence and quantity of autoimmune antibodies can thus be detected easily and rapidly via the color reaction.

15 Another diagnostic comprises the antibodies according to the invention themselves. These antibodies allow for example a human tissue sample to be examined easily and rapidly for the presence of the polypeptide in question. In this case, the antibodies according to the invention are labeled, for example with an enzyme as already described above. The specific antibody/peptide complex can thus be detected easily and equally rapidly via an enzymatic color reaction.

25 Another subject matter of the invention relates to a fungicide which comprises the nucleic acids according to the invention and/or the polypeptides according to the invention, singly or in combination, and, if appropriate, suitable additives or adjuvants, and to a process for the preparation of a fungicide for controlling harmful yeasts and harmful fungi, wherein a nucleic acid according to the invention or a polypeptide according to the invention is formulated together with agriculturally acceptable additives and/or adjuvants.

35 As already described, a transgenic plant is generated in a preferred embodiment which expresses the protein toxin according to the invention. The invention therefore also relates to plant cells and inherently to the transgenic plant as such comprising the polypeptides and/or protein toxins according to the invention.

Another subject of the present invention also relates to an assay for identifying functional interactors such as, for example, inhibitors or stimulators comprising a nucleic acid according to the invention, a polypeptide according to the invention or the antibodies according to the invention and, if appropriate, suitable additives and/or adjuvants.

A suitable assay for identifying functional interactors, in particular those which interact in the sensitive yeast cell with the protein toxin ZYGOCIN in accordance with **SEQ ID No 2** is, for example, the two-hybrid system (Fields, S. & Sternglanz, R. (1994) Trends in Genetics, 10, 286). In this assay, a cell, for example a yeast cell, is transformed or transfected with one or more expression vectors which express a fusion protein comprising the polypeptide according to the invention and a DNA binding domain of a known protein, for example Gal4 or LexA from *E. coli*, and/or express a fusion protein comprising an unknown polypeptide and a transcription activation domain, for example of Gal4, Herpes virus VP16 or B42. In addition, the cell comprises a reporter gene, for example the *E. coli* LacZ gene, green fluorescence protein or the yeast amino acid biosynthesis genes His3 or Leu2, which reporter gene is controlled by regulatory sequences such as, for example, the *lexA* promoter/operator or by a yeast upstream activation sequence (UAS). The unknown polypeptide is encoded for example by a DNA fragment which originates from a gene library, for example a human gene library. Usually, a cDNA gene library is first produced in yeast with the aid of the expression vectors described, so that the assay can be carried out immediately thereafter.

In a yeast expression vector, for example, the nucleic acid according to the invention is cloned in functional unit on the nucleic acid encoding the LexA DNA binding domain so that a fusion protein of the polypeptide according to the invention and the LexA DNA binding domain is expressed in the transformed yeast. In another yeast expression vector, cDNA fragments of a cDNA gene library are cloned in functional unit on the nucleic acid encoding the Gal4 transcription activation domain, so that a fusion protein of an unknown polypeptide and the Gal4 transcription activation domain is expressed in the transformed yeast. The yeast, for example *Leu2⁻*, which is transformed with both expression vectors additionally comprises a nucleic acid which encodes *Leu2* and which is controlled by the LexA promoter/operator. In the event of functional interaction between the polypeptide according to the invention and the unknown polypeptide, the

Gal4 transcription activation domain binds to the LexA promoter/operator via the LexA DNA binding domain, thus activating the LexA promoter/operator and expressing the Leu2 gene. As a consequence, the Leu2⁻ yeast is capable of growth on minimal medium which does not contain leucin.

When using the LacZ or green fluorescence protein reporter gene instead of an amino acid biosynthesis gene, transcriptional activation can be detected by the formation of colonies which fluoresce blue or green. However, the blue or green fluorescent stain can also be quantified easily in a spectrophotometer, for example at 585 nm in the case of blue staining.

In this manner, expression gene libraries can be screened easily and rapidly for polypeptides which interact with the polypeptide according to the invention. The novel polypeptides which have been found can subsequently be isolated, and characterized further.

Another possible use of the two-hybrid system consists in influencing the interaction between the polypeptide according to the invention and a known or unknown polypeptide by other substances, such as, for example, chemicals. This also allows novel valuable active ingredients to be found which can be synthesized chemically and employed as therapeutics. The present invention is therefore not only intended for a method of finding polypeptide-like interactors, but also extends to a method of finding substances which are capable of interacting with the above-described protein/protein complex. Such peptide-like, and chemical, interactors are therefore termed functional interactors for the purposes of the present invention which can have an inhibitory or stimulatory action.

Another subject matter of the invention relates to a process for the preparation of protein toxins by culturing and secreting the protein toxins into a medium which constitutes a synthetic culture medium (BAVC medium), which considerably facilitates chromatographic purification of the secreted toxins, for example by means of ultrafiltration and cation exchange chromatography and/or affinity chromatography on laminarin-Sepharose and/or mannoprotein-Sepharose [cf. Example 1 and Appendix to the Examples]. In the case of WICALTIN, which is produced and secreted by strain DSM 12865, the toxin production can be increased further by supplementing the medium with an addition of the plant-derived (and readily available) β -1,3-D-glucan laminarin in a final concentration of 1%.

As exemplified in Example 14, the addition of laminarin to the culture medium leads to induction of the WICALTIN production, and Northern analyses allowed this to be attributed to transcriptional induction.

Synthetic B medium can be employed to produce the toxin ZYGOCIN,
5 which is secreted by DSM 12864 [cf. Radler et al., 1993].

The examples which follow are intended to illustrate the invention without restricting the invention to these examples.

10 Examples

Example 1:

Isolation, concentration and purification of the anti-*Candida* toxin WICALTIN from culture supernatants of the killer yeast *W. californica* strain 3/57 (DSM 12865)

- 15 In the agar diffusion test on Methylene Blue agar against sensitive yeasts, the killer toxin WICALTIN secreted by the killer yeast *W. californica* 3/57 shows an optimal inhibitory action at pH 4.7 and 20°C. In synthetic liquid medium, the killer yeast *W. californica* strain 3/57 shows maximum toxin production when grown in BAVC medium (pH 4.7). For the purposes of
- 20 toxin concentration, the killer yeast was first incubated for 24 hours in 5 ml of YEPD medium at 30°C with shaking, then all of it was transferred into 200 ml of BAVC medium and again cultured for 48 hours at 20°C on the shaker (140 rpm). Four main cultures of 2.5 l BAVC medium each (pH 4.7 in 5-l Erlenmeyer flasks) were inoculated with the second preculture (1%
- 25 inoculum) and incubated for five days at 20°C with gentle shaking (60 rpm). To concentrate the secreted killer toxin, the cell-free culture supernatant was concentrated 200-fold to a volume of 50 ml by means of ultrafiltration on polysulfonic acid membranes ('EasyFlow' [Fa. Sartorius]; exclusion limit 10 kDa) at +4°C and a pressure of 1 bar. To remove low-molecular-weight
- 30 compounds and to desalinify the concentrate thus obtained, the toxin was dialyzed overnight at +4°C in a dialysis tube (exclusion limit 10-20 kDa) against 5 mM citrate/phosphate buffer (pH 4.7). To store the toxin concentrate, the dialyzed product was filter-sterilized through a 0.2-µm membrane and frozen at -20°C in 1-ml aliquots.
- 35 The toxin activity was detected and standardized in an agar diffusion test on Methylene Blue agar (MBA; pH 4.7) against the sensitive indicator yeast *Saccharomyces cerevisiae* 192.2d. To this end, logarithmic dilution steps of the toxin concentrate were prepared in 0.1 M citrate/phosphate buffer (pH 4.7), and 100-µl aliquots were pipetted into wells (well diameter 9 mm)

which had previously been punched into an MBA plate inoculated with the sensitive indicator yeast (2×10^5 cells/ml). After the plates had been incubated for three days at 20°C, the inhibition zones, which were clearly visible, were measured. It emerged that a linear relationship exists between the inhibition zone diameter and the logarithm of the toxin concentration. An arbitrary toxin activity of 1×10^4 units/ml was assigned to an inhibition zone diameter of 20 mm (corrected by the well diameter).

The concentrated WICALTIN was purified either by cation exchange chromatography on Bioscale-S (FPLC) or by affinity chromatography on an epoxy-activated Sepharose-6B matrix (Pharmacia) to which the plant-derived β -1,6-D-glucan pustulan had previously been coupled. The toxin preparation (**Table 1**), which had thus been enriched 625-fold in its specific activity, was gel-electrophoretically pure and, after SDS-PAGE (in a 10-22% gradient gel), only showed a single band at approximately 37 kDa, which was detectable both with Coomassie Blue (protein stain) and periodic acid - Schiff stain (PAS; carbohydrate stain). The positive PAS stain suggests a potential N-glycosylation of the anti-*Candida* toxin WICALTIN. Treatment of the purified toxin with endoglycosidase-H confirmed that WICALTIN has an N-glycosidically linked carbohydrate moiety of approximately 3 kDa, whose size, in yeast, also suggests a single N-glycosylation site in the protein toxin. Since the deglycosylated WICALTIN shows markedly restricted toxicity, it can be deduced that the carbohydrate moiety of WICALTIN is probably necessary for binding to the sensitive target cell and thus indirectly affects the bioactivity of the toxin.

Table 1: Concentration of WICALTIN from the culture supernatant of the killer yeast *Williopsis californica* [UF, Ultrafiltration]

Preparation	Volume [ml]	Total protein [mg]	Total toxin activity [E]	Specific toxin activity [E/mg]	Activity yield [%]	Purification factor
Culture supernatant	10,000	24,600	7.9×10^5	3.2×10^1	100	1
UF retentate	50	162	6.3×10^5	3.9×10^3	80	122
Lyophilized dialysate	25	45.8	3.1×10^5	6.8×10^3	39	213
Bio-Scale S (cation exchange)	64	1.28	2.5×10^4	2.0×10^4	3.2	625

5 Example 2:

Determination of the NH₂-terminal amino acid sequence of WICALTIN, and detection of an enzymatic β -1,3-glucanase activity

The first ten amino acids were determined by sequencing the N-terminal amino acids of the purified killer toxin. As can be seen from **Figure 1**, the
10 N-terminus of WICALTIN shows significant homology to the amino terminus of the endo- β -1,3-glucanase encoded by the *BGL2* gene of the yeast *Saccharomyces cerevisiae*.

Since the homology of WICALTIN and Bgl2 had been determined, the possibility of detecting a glucanase activity in the unpurified toxin concentrate and in the purified toxin preparation was investigated. In the
15 WICALTIN preparations, a pronounced β -1,3-D-glucanase activity was detected both in the enzyme assay with the β -1,3-D-glucan laminarin as substrate and in the fluorescence assay with 4-methyl-umbelliferyl- β -D-glucoside (MUC) as substrate; the β -1,6-D-glucan pustulan, which was also
20 tested, was not hydrolyzed by WICALTIN.

Example 3:

Survival rates of WICALTIN-treated yeast cells in the presence and absence of cell wall glucans: competition analyses

Sensitive yeast cells of strain *S. cerevisiae* 192.2d which are grown in YEPD liquid medium (pH 4.7) at 20°C in the presence of 1×10^5 U/ml purified WICALTIN showed the kill kinetics shown in **Figure 2**. Addition of the plant-derived β -1,6-D-glucan pustulan allowed the survival rate of toxin-treated yeast cells to be increased significantly and fully reversed WICALTIN toxicity when added at concentrations of 10 mg/ml. As opposed to pustulan, the β -1,3-D-glucan laminarin was not capable of increasing the survival rate of the toxin-treated yeasts (**Figure 2**).

The findings shown therefore allow the conclusion that the action of WICALTIN requires a binding to β -1,6-D-glucans which act as primary docking sites (toxin receptors) of the yeast cell wall. In agreement with this finding, it was shown that yeasts with a deletion in the chromosomal *KRE1* gene locus show toxin resistance, but regain toxin sensitivity when retransformed with an episomal vector which carries *KRE1* (**Figure 3**). The toxin resistance in *kre1* mutants is based on a markedly reduced β -1,6-D-glucan content and thus a reduced toxin binding to the yeast cell surface, which is required for the lethal action.

Example 4:

Spectra of action and kill spectra of WICALTIN

In the agar diffusion test, the purified *W. californica* toxin WICALTIN exhibited a pronounced toxicity against the yeasts shown in **Table 2**. With the exception of three strains of the yeast *Candida krusei*, all the 22 clinical patient isolates which were tested and all the other control strains of *Candida* species which are pathogenic for man were destroyed by WICALTIN in a highly efficient manner. With 14 toxin-sensitive yeast species from a total of 10 different genera, WICALTIN shows a spectrum of action which is unusually broad for killer toxins.

Table 2: Spectrum of action of WICALTIN on pathogenic and apathogenic yeasts of different genera. All strains were tested in the agar diffusion test (MBA; pH 4.7) against purified WICALTIN. The toxin activity applied was 1×10^6 U/ml. The strain *C. tropicalis* (patient number 541965) was obtained from the Department of Medical Microbiology and Hygiene of the University Hospital Mainz.

Yeast strain	Pheno-type	Inhibitory zone diameter [mm]
<i>Candida albicans</i> ATCC 10231	S	11
<i>C. glabrata</i> NCYC 388	S	12
<i>C. krusei</i> 185	R	0
<i>C. tropicalis</i> patient number 541965	S	11
<i>Debaryomyces hansenii</i> 223	S	16
<i>Hanseniaspora uvarum</i> ATCC 64295	R	0
<i>Hasegawaea japonica</i> var. <i>Versatilis</i> 191	R	0
<i>Kluyveromyces lactis</i> CBS 2359/152	S	22
<i>K. marxianus</i> C 8,1	R	0
<i>Metschnikowia pulcherrima</i> K/3l B6	S	8
<i>Pichia anomala</i> 245	S	17
<i>P. farinosa</i> 258	R	0
<i>P. jadinii</i> 251	S	6
<i>P. kluyveri</i> ATCC 64301	R	0
<i>P. membranaefaciens</i> NCYC 333	R	0
<i>Saccharomyces cerevisiae</i>		
192.2d	S	30
381	S	23
ATCC 42017 (K1 superkiller)	S	19
NCYC 738 (K2 killer)	S	14
452 (= NCYC 1006)	S	16
<i>Saccharomycodes ludwigii</i> 240	R	0
<i>Schizosaccharomyces pombe</i> CBS1042	R	0
<i>Sporothrix</i> spec. 1129	S	11
<i>Torulospora delbrueckii</i> 208	S	18
<i>T. pretoriensis</i> 186	S	10
<i>Yarrowia lipolytica</i> 271	S	8
<i>Zygosaccharomyces bailii</i> 412	S	23

Example 5:

Cloning, sequencing and molecular characterization of the WICALTIN-encoding *WCT* gene of the yeast *W. californica* strain 3/57 (DSM 12865)

5

Starting with the N-terminal amino acid sequence of WICALTIN, specific DNA oligonucleotides were generated which led to the identification and cloning, and to the characterization of the molecular biology of the toxin

gene *WCT*, which is located chromosomally. The DNA sequence of *WCT* (SEQ ID No. 1) shows a single open reading frame which encodes a potentially N-glycosylated protein of 309 amino acids and a calculated molecular weight of 34,017 Da. Studies into the action of the *WCT* encoded killer toxin showed that WICALTIN is a glycoprotein which is extremely toxic to yeasts and whose primary targets are the cell wall β -1,3-D-glucans found in yeasts. Its selective toxicity to yeasts and fungi is based on WICALTIN destroying the cell wall structure and/or integrity in the sensitive target cell, and thus attacking yeasts where they are most sensitive, finally killing them.

Example 6:

Concentration and purification of the viral toxin ZYGOCIN from culture supernatants of the killer yeast *Z. bailii* strain 412 (DSM 12864)

The virus-encoded killer toxin ZYGOCIN of the yeast *Z. bailii* strain 412 was isolated from the culture supernatant of the killer yeast by the method described by Radler *et al.* (1993), concentrated by ultrafiltration and finally purified by affinity chromatography. The one-step purification of ZYGOCIN, which was developed in the present study, exploits the natural affinity of the toxin to cell wall mannoproteins of sensitive yeasts. The mannoprotein, which was isolated and partially purified from *S. cerevisiae* strain 192.2d by a method described by Schmitt & Radler (1997), was coupled covalently to an epoxy-activated Sepharose-6B matrix (Pharmacia) and employed by means of FPLC for purifying the toxin by column chromatography. Following SDS-PAGE, the highly bioactive ZYGOCIN which had been purified in this manner showed a single protein band with an apparent molecular weight of approximately 10 kDa (Figure 4).

Example 7:

Spectrum of action and kill spectrum of ZYGOCIN

The spectrum of action of viral ZYGOCIN of the yeast *Z. bailii* 412 (DSM 12864) which was determined in the agar diffusion test comprises pathogenic and apathogenic yeast genera, amongst which *Candida albicans* and *Sporothrix schenckii* are important pathogens in humans and animals, and *Ustilago maydis* and *Debaryomyces hansenii* are important harmful yeasts in agriculture and in the food sector (Tab. 3).

Table 3: Spectrum of action of ZYGOCIN to pathogenic and apathogenic yeasts of different genera. All strains were tested in the agar diffusion test

(MBA; pH 4.5) against the ZYGOCIN preparation with an activity of 1×10^4 U/ml.

ZYGOCIN-sensitive yeasts	Relative degree of sensitivity
<i>Saccharomyces cerevisiae</i>	++
<i>Candida albicans</i>	+
<i>Candida krusei</i>	++
<i>Candida glabrata</i>	++
<i>Candida vinii</i>	+
<i>Hanseniaspora uvarum</i>	++
<i>Kluyveromyces marxianus</i>	+
<i>Metschnikowia pulcherrima</i>	+
<i>Ustilago maydis</i>	++
<i>Debaryomyces hansenii</i>	++
<i>Pichia anomala</i>	++
<i>Pichia jadinii</i>	+
<i>Pichia membranefaciens</i>	+
<i>Yarrowia lipolytica</i>	+
<i>Zygosaccharomyces rouxii</i>	++

5 Example 8:

Cloning and sequencing of the ZYGOCIN-encoding ZBT gene (ZBT) of the yeast *Z. bailii* strain 412 (DSM 12864)

The cDNA of the toxin-encoding double-stranded RNA genome of the killer yeast *Z. bailii* 412 was synthesized out by a method similar to that described by Schmitt (1995) using purified M-dsRNA which had been denatured with methylmercury hydroxide as template and various hexanucleotides as primers. After ligation into the EcoRI-restricted vector pUC18, transformation in *E. coli* and isolation of the recombinant plasmids identified, several cDNA clones were isolated and sequenced. The cDNA sequence of the ZYGOCIN-encoding reading frame (**SEQ ID No 2**) contains the genetic information for a precursor protein (pro-toxin) of 238 amino acids, which carries a potential Kex2-endopeptidase cleavage site in the amino acid position RR¹³⁹. The bioactive ZYGOCIN, whose molecular weight (10 kDa; 99 amino acids) and N-terminal amino acid sequence exactly agree with the data determined for the purified ZYGOCIN, is formed

by Kex2-mediated pro-ZYGOCIN-processing, which takes place *in vivo* during the late Golgi stage.

Owing to the toxicity of ZYGOCIN, heterologous expression of the *ZBT*-cDNA in the yeast *S. cerevisiae* resulted in the transformed yeasts killing themselves by their own toxin. A future aim will be heterologous ZYGOCIN expression in the toxin-resistant fission yeast *Schizosaccharomyces pombe* since, as has already been demonstrated by way of example of the viral K28 toxin, the fission yeast is particularly suitable for expressing or secreting foreign proteins.

Example 9:

Expression of the toxin genes *WCT* and *ZBT* in transgenic plants

Since the above-described killer toxins WICALTIN and ZYGOCIN have a broad spectrum of action and also destroy plant-pathogenic yeasts and fungi, it should be possible to construct transgenic plants which show resistance to, for example, an infection with the maize pathogen *Ustilago maydis*. Similar experiments have already been carried out on tobacco plants which, owing to heterologous expression of the *U. maydis* killer toxin KP4, which is encoded virally in nature, were capable of secreting the killer toxin in question and which thus generated a specific protection from infection with certain phytopathogenic *U. maydis* strains (Park et al., 1996; Kinal et al., 1995; Bevan, 1984). Starting with commercially available transformation systems based on modified derivatives of the natural *Agrobacterium tumefaciens* Ti-Plasmid, it is possible to clone the toxin genes *WCT* and *ZBT*, which we have cloned, into so-called bidirectional pBI vectors (CLONTECH) and to use them for the generation of transgenic plants. To this end, the toxin genes in question, *WCT* and *ZBT*, are placed under the transcriptional control of the strong cauliflower mosaic virus promoter (CaMV-P). The construction of the vectors to be constructed is shown schematically in **Figure 5**.

Example 10:

Heterologous expression of the WICALTIN-encoding *WCT* gene of the yeast *W. californica* 3/57 (DSM 12865) in *S. cerevisiae*

To express the *WCT* gene heterologously in the yeast *S. cerevisiae*, the WICALTIN-encoding *WCT* gene was cloned as a 930 bp *EcoRI*/*SmaI* fragment into the 2μ vector pYX242, which is generally available. The resulting vector pSTH2 (**Figure 6**) comprises the toxin gene under the transcriptional control of the yeast's triose phosphate isomerase promoter

(*TPI*) and thus allows the constitutive expression of WICALTIN after transformation into yeast (*S. cerevisiae*). An analysis by gel electrophoresis of the culture supernatant of the yeast transformants obtained in this manner showed that the recombinant WICALTIN is secreted into the external medium and has a β -1,3-D-glucanase activity which corresponds to that of the homologous WICALTIN (from wild-type strain DSM 12865); (Figure 6).

Example 11:

10 **Experiments on the heterologous expression of WICALTIN and ZYGOCIN in the fission yeast *Schizosaccharomyces pombe***

Since the fission yeast shows resistance to WICALTIN and ZYGOCIN, both as intact cell and as a cell-wall-free spheroplast, it is suitable as host for the heterologous expression of the toxins in question. To ensure that the recombinant toxins are not only expressed by the fission yeast, but simultaneously also fed into the intracellular secretional pathway and thus secreted into the external medium, a vector was constructed (pTZ α /Y; Figure 7) which carries a secretion and processing signal (S/P) which is functional in *S. pombe* and which is derived from the cDNA of the viral K28-preprotoxin gene of the yeast *S. cerevisiae* [c.f. Schmitt, 1995; Schmitt & Tipper, 1995]. The secretion and processing signal ensures that the foreign protein, which is arranged downstream in-frame, is imported in the fission yeast into the lumen of the endoplasmatic reticulum and thus fed into the secretional pathway of the yeast. The Kex2p cleavage site which is present on the C-terminus of the S/P-region causes the desired foreign protein to be cleaved off from its intracellular transport vehicle in a late Golgi compartment by the yeast's Kex2p-endopeptidase, and it can finally be secreted into the external medium as bioactive protein (ZYGOCIN and/or WICALTIN).

30

Example 12:

Comparative bioactivities of purified WICALTIN and the topical antimycotics clotrimazole and miconazole

Since purified WICALTIN has a broad spectrum of action and also efficiently kills yeasts and/or fungi which are pathogenic for man it is important as a candidate antimycotic. Thus, comparative studies were carried out on WICALTIN with the topical antimycotics clotrimazole and miconazole, which are currently widely employed. First, the toxic effect of clotrimazole and miconazole against *Sporothrix spec.* as indicator yeast

35

was tested in the MBA agar diffusion test. To this end, clotrimazole was dissolved in ethanol (96%) in a concentration of 10 mg/ml; this stock solution was diluted with ddH₂O and employed in the MBA test in concentrations of 0.1 to 10 mg/ml per 100 µl. When an amount of 10-50 µg of clotrimazole was employed, the inhibitory zone diameters were between 12 and 32 mm. Miconazole was used to prepare a stock solution of 100 µg/ml in DMSO (100%), and this was tested in the same manner as clotrimazole in the MBA test for bioactivity against *Sporothrix* spec. In the bioassay, the use of 0.08-0.3 µg of miconazole resulted in inhibitory zones between 22 and 36 mm. The bioactivities of 10 µg of clotrimazole and 0.08 µg of miconazole thus correspond to the toxicity of 2 µg of purified WICALTIN. A comparison based on the molecular weight of the three test compounds shows that even at a concentration of 0.07 pmol WICALTIN shows the same activity as 0.2 pmol miconazole and 29 pmol clotrimazole; WICALTIN is thus an extremely potent antimycotic (**Figure 8**).

Example 13:

Detection of the WICALTIN-encoding *WCT* gene of the yeast *W. californica* 3/57 (DSM 12865) by Southern hybridization with a gene-specific DNA probe.

To prove that the nucleic acid in accordance with **SEQ ID No. 1** can be employed to generate a WICALTIN-specific DNA probe for a subsequent Southern hybridization, a DIG-labeled 930 bp DNA probe was employed for detecting the *WCT* gene which had been cloned into the vector pSTH1. The constructed vector pSTH1 represents a derivative of the procaryotic cloning vector pBR322, which is generally available.

The agarose gel electrophoresis shown in **Figure 9** and the corresponding Southern blot show beyond doubt that the nucleic acid probe can be used to detect the WICALTIN-encoding *WCT* gene.

Example 14:

Northern blot analysis for detecting a transcriptional induction of the WICALTIN-encoding *WCT* gene of the yeast *Williopsis californica* 3/57 (DSM 12865) by β -1,3-D-glucans

To detect a β -1,3-D-glucan-induced *WCT* transcription, the yeast strain DSM 12865 was grown in 300 ml of BAVC medium or in BAVC medium supplemented with 0.03% of the plant-derived β -1,3-D-glucan laminarin for 48 hours at 20°C and gentle shaking (60 rpm) and, after different intervals, used for preparing total RNA. Before the RNA isolation, all samples (10 ml)

were brought to an identical cell density of 1.8×10^8 cells/ml and separated by electrophoresis in denaturing agarose formaldehyde gels. As can be seen from **Figure 10**, a size of 1100 bases was detected for the *WCT* transcript both under noninducing conditions (BAVC medium without supplementation) and in the laminarin supplemented BAVC medium. Without addition of glucan, maximum *WCT* expression was achieved toward the end of the exponential growth phase (after 19 hours); the hybridization signals, which turn markedly weaker in the stationary growth phase, suggest a reduced transcription. Under inducing culture conditions (in the presence of laminarin), the *WCT* transcript shows a much higher intensity after 10 hours than in the noninduced culture, allowing the conclusion that transcription of the *WICALTIN*-encoding *WCT* gene can be induced by addition of β -1,3-D-glucans.

Appendix to the examples:

Media and solutions used in the examples:

a.) BAVC medium

20	glucose	50 g/l	
	D,L-malate	20 g/l	
	trisodium citrate	0.5 g/l	
	(NH ₄) ₂ SO ₄	1.5 g/l	
	MgSO ₄	1.0 g/l	
25	CaCl ₂	0.5 g/l	
	myo-inositol	0.04 g/l	
	amino acid stock solution (10 x)	200 ml/l	
	trace element stock solution (100 x)	10 ml/l	
	vitamin stock solution (100 x)	20 ml/l	

30

with:

b.) Amino acid stock solution (10 x)

35	alanine	0.75 g/l
	arginine monohydrochloride	3.5 g/l
	aspartic acid	0.5 g/l
	glutamic acid	3 g/l
	histidinium monochloride	0.2 g/l

- 28 -

methionine	0.4 g/l
serine	0.5 g/l
threonine	2 g/l
tryptophan	0.4 g/l

5

c.) Trace element stock solution (100 x)

	boric acid	200 mg/l
	FeCl ₃ x 6 H ₂ O	200 mg/l
10	ZnSO ₄ x 7 H ₂ O	200 mg/l
	AlCl ₃	200 mg/l
	CuSO ₄ x 5 H ₂ O	100 mg/l
	Na ₂ MoO ₄ x 2 H ₂ O	100 mg/l
	Li ₂ SO ₄ x H ₂ O	100 mg/l
15	KI	100 mg/l
	potassium hydrogen tartrate	2 g/l

d.) Vitamin stock solution (100 x)

20	4-aminobenzoic acid	20 mg/l
	biotin	2 mg/l
	folic acid	2 mg/l
	nicotinic acid	100 mg/l
	pyridoxin hydrochloride	100 mg/l
25	riboflavin	50 mg/l
	thiamineium dichloride	50 mg/l
	calcium D-pantothenate	100 mg/l

Biotin: dissolve in 5 g KH₂PO₄/50 ml distilled water.

30 Folic acid: dissolve in 50 ml of distilled water with addition of a few drops of dilute NaOH.

Riboflavin: dissolve in 500 ml of distilled water and a few drops of HCl with heating.

The remaining vitamins can be dissolved in a little distilled water.

35

The pH of the BAVC medium was brought to pH 4.7 by addition of KOH. The glucose and stock solutions were sterilized separately. Amino acid, vitamin and trace element stock solutions were sterilized for 20 minutes at

100°C with the valve open and were then added to the autoclaved BAVC medium.

Figures and the most important sequences

5

SEQ ID No. 1: DNA sequence and deduced amino acid sequence of the *WCT*-encoded protein toxin WICALTIN of the yeast *Williopsis californica* strain 3/57.

10

SEQ ID No. 2: cDNA sequence and deduced amino acid sequence of the *ZBT*-encoded protein toxin ZYGOCIN of the yeast *Z. bailii*

15

Figure 1: N-terminal amino acid sequences of the *W. californica* toxin WICALTIN and of the endo- β -1,3-glucanase Bgl2 of the yeast *S. cerevisiae*. The only deviation of the subsequences, which are otherwise identical, is shown in bold (Bgl2p sequence after Klebl & Tanner, 1989)

20

Figure 2: Kill kinetics of WICALTIN-treated cells of the sensitive yeast *S. cerevisiae* 192.2d in the presence (2a) and absence (2b) of the β -D-glucans laminarin (L) and pustulan (P). The toxin employed had a total activity of 4.0×10^5 U/ml at a specific activity of 4.2×10^5 U/mg protein.

25

Figure 3 (a,b,c,d): Agar diffusion test for detecting a WICALTIN sensitivity/resistance in $Kre1^+$ and $Kre1^-$ strains of the yeast *S. cerevisiae*. Transformation of the WICALTIN-resistant *kre1* zero-mutant *S. cerevisiae* SEY6210[$\Delta kre1$] with the *KRE1*-carrying vector pPGK[*KRE1*] fully restores the WICALTIN sensitivity.

30

Figure 4: (A) Analysis by gel electrophoresis (SDS-PAGE) of the ZYGOCIN produced and secreted by the yeast *Z. bailii* strain 412 (DSM 12864) after affinity chromatography on mannoprotein-Sepharose. (B) Agar diffusion test for detecting the bioactivity of the purified killer toxin ZYGOCIN.

35

Figure 5: Schematic construction of a *ZBT*- or *WCT*-carrying expression vector for the generation of transgenic plants.

[Key: RB, LB: right and left border sequences of the natural Ti-plasmid of *Agrobacterium tumefaciens*; CaMV-P: cauliflower mosaic virus 35S promoter; NOS-P, NOS-T: nopaline synthase transcription promoter and

terminator; kan^R: *Streptococcus* kanamycin resistance gene for selection in *E. coli*; NPT-II: neomycin phosphotransferase gene from transposon Tn5 for selection in the plant].

- 5 **Figure 6:** (A) Partial restriction map of the episomal vector pSTH2 for the heterologous expression of the WICALTIN-encoding toxin gene *WCT* in the yeast *Saccharomyces cerevisiae*. Vector pSTH2 is a constructed plasmid based on the commercially available 2 μ multi-copy vector pYX242 into which the *WCT*-gene from strain DSM 12865 was cloned as a 930 bp
- 10 *EcoRI/SmaI* fragment. The toxin gene in question is under the transcriptional control of the yeast's *TPI* promoter and thus allows the strong and constitutive expression of WICALTIN after transformation into *S. cerevisiae*.
- (B) Analysis by gel electrophoresis (SDS-PAGE; 10-22.5% gradient gel) of concentrated culture supernatants of *S. cerevisiae* after transformation with the constructed WICALTIN expression vector pSTH2 (lane 1) and the basic vector pYX242 (lane 2). The WICALTIN which has been expressed heterologously in *S. cerevisiae* is marked by an arrow.
- 15 (C) Detection of extracellular β -1,3-D-glucanase activity of the yeast *S. cerevisiae* after transformation with the WICALTIN-expressing yeast vector pSTH2. To determine the exo- β -1,3-D-glucanase activity, the yeast colonies which have been grown on leucin-free SC agar were sprayed with 0.04% 4-methylumbelliferyl- β -D-glucoside (MUG) in 50 mM sodium acetate buffer (pH 5.2). After incubation at 37°C for 30 minutes, the agar plates were irradiated with UV light (wavelength 254 nm). Glucanase activity was detected by the fluorescence owing to MUG hydrolysis.
- 20 [Key: 1 and 4, *S. cerevisiae* transformed with a vector (pEP-WCT) which expresses the WICALTIN-encoding *WCT* gene under its own promoter; 2, wild-type yeast *W. californica* 3/57 (DSM 12865); 3, wild-type yeast
- 25 *W. californica* 3/111; 5, *S. cerevisiae* after transformation with the WICALTIN-expressing vector pYX-WCT; 6, *S. cerevisiae* transformed with the basic vector pYX242 (without toxin gene)]
- 30

- 35 **Figure 7:** Scheme of the structure of vector pTZ α/γ for the heterologous expression and secretion of foreign proteins (in particular WICALTIN and ZYGOCIN) in the fission yeast *Schizosaccharomyces pombe*.

[Key: P_{nmt1}, T_{nmt1}, transcription promoter and transcription terminator of the thiamine-regulated *nmt1* gene of the fission yeast *S. pombe*; S/P, secretion and processing sequence of the viral K28 preprotoxin of the

budding yeast *S. cerevisiae*; *ars1*, autonomously replicating sequence from chromosome 1 of the fission yeast; *leu2*, leucine-2 marker gene for the selection of leucine-prototrophic *S. pombe* transformer]

- 5 **Figure 8:** Comparison of the bioactivities of purified WICALTIN, clotrimazole and miconazole; in the bioassay (agar diffusion test) against the sensitive indicator yeast *Sporothrix* spec., the molar quantities indicated produce an inhibitory zone diameter of 12 mm.
- 10 **Figure 9:** Detection of the WICALTIN-encoding *WCT* gene of the yeast *W. californica* 3/57 (DSM 12865), cloned into pSTH1 (pBR322 derivative), by agarose gel electrophoresis (A) and Southern hybridization with a DIG-labeled *WCT* probe (B).
- [Key: M, DIG-labeled DNA size standard II; lane 1, pSTH1 restricted with
- 15 *Eco*RI and *Sal*I; lane 2, "smart ladder" DNA marker]

Figure 10: Northern analysis of the transcriptional induction of the WICALTIN-encoding *WCT* gene of the yeast *W. californica* 3/57 (DSM 12865) under noninducing culture conditions in BAVC medium (A) and

20 under inducing conditions in BAVC medium supplemented with 0.03% laminarin (B). The total RNA isolated from strain DSM 12865 was separated by electrophoresis in a denaturing agarose/formaldehyde gel at constant voltage (7 V/cm). The RNA was hybridized on a nylon membrane against a WICALTIN-specific, DIG-labeled DNA probe (630 bp) and

25 detected by chemiluminescence.

[Key: M, DIG-labeled RNA size standard I; lanes 1-8 correspond to the sampling times to isolate total RNA: lane 1, 10 hours; lane 2, 15 hours; lane 3, 19 hours; lane 4, 24 hours; lane 5, 33 hours; lane 6, 38 hours; lane 7, 43 hours; lane 8, 48 hours]

30 Abbreviations used in the text:

WCT	Williopsis Californica Toxin
ZBT	Zygosaccharomyces Bailii Toxin
ZYGOCIN	Proper name; secreted toxin from DSM 12864
WICATIN	Proper name; secreted toxin from DSM 12865

Deposits

- The following microorganisms used for the purposes of the present invention were deposited at the Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), - Maschenroder Weg 1b, 38124 Braunschweig, Federal Republic of Germany – which is recognized as international depository in compliance with the provisions of the Budapest Treaty on the international recognition of the deposit of microorganisms for the purposes of patent procedure
- 5
- 10 (deposit number; deposit date):

<i>Williopsis californica</i> strain 3/57	(DSM 12865)	(09.06.1999)
<i>Zygosaccharomyces bailii</i> strain 412	(DSM 12864)	(09.06.1999)

References

- Anaissie, E. (1992).** Opportunistic mycoses in the immuno compromised host: experience at a cancer center and review. *Clin. Infect. Dis.* 14:43-51.
- Bevan, E.A. & M. Makower (1963).** The physiological basis of the killer character in yeast. *Proc. Int. Congr. Genet.* XI:1202-1203.
- Bevan, M. (1984).** Binary *Agrobacterium* vectors for plant transformation. *Nucl. Acids Res.* 12:8711-8720.
- Bussey, H. (1991).** K1 killer toxin, a pore-forming protein from yeast. *Mol. Microbiol.* 5:2339-2343.
- Cameron, M.L., Schell, W.A., Bruch, S., Bartlett, J.A., Waskin, H.A. & J.R. Perfect (1993).** Correlation of in vitro fluconazole resistance of *Candida* isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. *Antimicrob. Agents Chemother.* 37:2449-2453.
- Chavenet, P., Lopez, J., Grappin, M., Bannin, A., Duong, M., Waldner, A., Buisson, M., Camerlynck, P. & H. Portier (1994).** Cross-sectional study of the susceptibility of *Candida* isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients. *AIDS* 8:945-950.
- Dignard, D., Whiteway, M., Germain, D., Tessier, D. & D.Y. Thomas (1991).** Expression in yeast of a cDNA copy of the K2 killer toxin gene. *Mol. Gen. Genet.* 227:127-136.
- Hanes, S.D., Burn, V.E., Strley, S.L., Tipper, D.J. & D.Y. Thomas (1986).** Expression of a cDNA derived from the yeast killer preprotoxin gene: implications for processing and immunity. *Proc. Natl. Acad. Sci. USA* 83:1675-1679.
- Hector, R.F. (1993).** Compounds active against cell walls of medically important fungi. *Clin. Microbiol. Rev.* 6:1-21.
- Hodgson, V.J., Button, D. & G.M. Walker (1995).** Anti-*Candida* activity of a novel killer toxin from the yeast *Williopsis mrakii*. *Microbiol.* 141:2003-2012.
- Kinal, H., Park, C.M., Berry, J., Koltin, Y. & J.A. Bruenn (1995).** Processing and secretion of a virally encoded antifungal toxin in transgenic tobacco plants: evidence for a Kex2p pathway in plants. *Plant Cell* 7:677-688.
- Klebl, F. & W. Tanner (1989).** Molecular cloning of a cell wall exo-b-1,3-glucanase from *Saccharomyces cerevisiae*. *J. Bacteriol.* 171:6259-6264.
- Komijama, T., Shirai, T., Ohta, T., Urakami, H., Furuichi, Y. & Y. Ohta (1998).** Action properties of HYI killer toxin from *Williopsis saturnus* var.

- saturnus*, and antibiotics, aculeacin A and paulacandin B. *Biol. Pharm. Bull.* 21:1013-1019.
- Kurz, M.B. (1998).** New antifungal drug targets: a vision for the future. *ASM News* 64:31-39.
- 5 **Levy, J.A. (1993).** Pathogenesis of human immunodeficiency virus infections. *Microbiol. Rev.* 57:183-289.
- Maenza, J.R., Keruly, J.C., Moore, R.D., Chaisson, R.E., Merz, W.G. & J.E. Gallant (1996).** Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients. *J. Infect. Dis.* 173:219-225.
- 10 **McCracken, D.A., Martin, V.J., Stark, M.J.R. & P.L. Bolen (1994).** The linear-plasmid-encoded toxin produced by the yeast *Pichia accaciae*: characterization and comparison with the toxin of *Kluyveromyces lactis*. *Microbiol.* 140:425-431.
- 15 **Meunier, F., Aoun, M. & N. Bitar (1992).** Candidemia in immunocompromised patients. *Clin. Infect. Dis.* 14:120-125.
- Mrsa, V., Klebl, F. & W. Tanner (1993).** Purification and characterization of the *Saccharomyces cerevisiae* BGL2 gene product, a cell wall endo- β -1,3-glucanase. *J. Bacteriol.* 175:2102-2106.
- 20 **Neuhausen, F. & M.J. Schmitt (1996).** Transgenic expression of a toxin-coding killer virus of the yeast *Zygosaccharomyces bailii* in *Saccharomyces cerevisiae*: genetic evidence for a possible function of "cryptic" mycoviruses in the evolution of their hosts. In: Transgenic Organisms and Biosafety: Horizontal Gene Transfer, Stability of DNA, and Expression of Transgenes, Schmidt, E.R. & Th. Hankeln (eds), 117-124, Springer-Verlag.
- 25 **Park, C.M., Banerjee, N., Koltin, Y. & J.A. Bruenn (1996).** The *Ustilago maydis* virally encoded KP1 killer toxin. *Mol. Microbiol.* 20:957-963.
- Park, C.M., Berry, J.O. & J.A. Bruenn (1996).** High-level secretion of a virally encoded anti-fungal toxin in transgenic tobacco plants. *Plant Mol. Biol.* 30:359-366.
- 30 **Pfaller, M.A., Chalberg, J.R., Redding, S.W., Smith, J., Farinacci, G., Fothergill, A.W. & M.G. Rinaldi (1994).** Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of *Candida albicans* from patients with AIDS and oral candidiasis. *J. Clin. Microbiol.* 32:59-64.
- 35 **Pfeiffer, P., Radler, F., Caspritz, G. & H. Hänel (1988).** Effect of a killer toxin of yeast on eukaryotic systems. *Appl. Environ. Microbiol.* 54:1068-1069.

- Polonelli, L., Lorenzini, R., De Bernadis, F. & G. Morace (1986). Potential therapeutic effect of yeast killer toxin. *Mycopathology* 96:103-107.
- Radler, F., Herzberger, S., Schöning, I. & P. Schwarz (1993). Investigation of a killer strain of *Zygosaccharomyces bailii*. *J. Gen. Microbiol.* 139:495-500.
- 5 Rex, J.H., Rinaldi, M.G. & M.A. Pfaller (1995). Resistance of *Candida* species to fluconazole. *Antimicrob. Agents Chemoth.* 39:1-8.
- Roemer, T., Paravicini, G., Payton, M.A. & H. Bussey (1994). Characterization of the yeast (1-6)- β -glucan biosynthetic components, Kre6p and Skn1p, and genetic interactions between the *PKC1* pathway and extracellular matrix assembly. *J. Cell. Biol.* 127:567-579.
- 10 Schmitt, M.J. & D.J. Tipper (1990). K28, a new double-stranded RNA killer virus of *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 10:4807-4815.
- Schmitt, M.J. & D.J. Tipper (1992). Genetic analysis of maintenance and expression of L and M double-stranded RNAs from yeast killer virus K28. *Yeast* 8:373-384.
- 15 Schmitt, M.J. & D.J. Tipper (1995). Sequence of the M28 dsRNA: preprotoxin is processed to an α/β heterodimeric protein toxin. *Virology* 213:341-351.
- 20 Schmitt, M.J. & F. Neuhausen (1994). Killer toxin-secreting double-stranded RNA mycoviruses in the yeasts *Zygosaccharomyces bailii* and *Hanseniaspora uvarum*. *J. Virol.* 68:1765-1772.
- Schmitt, M.J. & F. Radler (1987). Mannoprotein of the yeast cell wall as primary receptor for the killer toxin of *Saccharomyces cerevisiae* strain 28. *J. Gen. Microbiol.* 133:3347-3354.
- 25 Schmitt, M.J. & F. Radler (1988). Molecular structure of the cell wall receptor for killer toxin K28 in *Saccharomyces cerevisiae*. *J. Bacteriol.* 170:2192-2196.
- Schmitt, M.J. & F. Radler (1995). Mycoviren und Hefe-Killertoxine erlauben Einblicke in die Zellbiologie [Mycoviruses and yeast-killer toxins permit insights into cell biology]. *Forschungsmagazin der Johannes Gutenberg-Universität Mainz* 2:86-96.
- 30 Schmitt, M.J. & F. Radler (1996). dsRNA-Viren codieren Killertoxine bei der Hefe *Saccharomyces* [DsRNA viruses encode killer toxins in the yeast *Saccharomyces*]. *BioEngineering* 2:30-34.
- 35 Schmitt, M.J. & G. Schernikau (1997). Construction of a cDNA-based K1/K2/K28 triple killer strain of *Saccharomyces cerevisiae*. *Food Technol. Biotechnol.* 35:281-285.

- Schmitt, M.J. & P. Compain (1995).** Killer toxin resistant *kre12* mutants of *Saccharomyces cerevisiae*: genetic and biochemical evidence for a secondary K1 membrane receptor. *Arch. Microbiol.* 164:435-443.
- Schmitt, M.J. (1995).** Cloning and expression of a cDNA copy of the viral K28 killer toxin gene in yeast. *Mol. Gen. Genet.* 246:236-246.
- Schmitt, M.J., Brendel, M., Schwarz, R. & F. Radler (1989).** Inhibition of DNA synthesis in *Saccharomyces cerevisiae* by yeast killer toxin K28. *J. Gen. Microbiol.* 135:1529-1535.
- Schmitt, M.J., Klavehn, P., Wang, J., Schöning, I. & D.J. Tipper (1996).** Cell cycle studies on the mode of action of yeast K28 killer toxin. *Microbiol.* 142:2655-2662.
- Schmitt, M.J., Poravou, O., Trenz, K. & K. Rehfeldt (1997).** Unique double-stranded RNAs responsible for the anti-*Candida* activity of the yeast *Hanseniaspora uvarum*. *J. Virol.* 71:8852-8855.
- Schmitt, M.J., Poravou, O., Trenz, K. & K. Rehfeldt (1997).** Unique double-stranded RNAs responsible for the anti-*Candida* activity of the yeast *Hanseniaspora uvarum*. *J. Virol.* 71:8852-8855.
- Schründer, J., Meinhardt, F., Rohe, M. & J. Kämper (1994).** Lineare Plasmide bei Mikroorganismen - Genetische Grundlagen and potentielle Anwendungen [*linear plasmids in microorganisms- genetic principles and potential applications*]. *BioEngineering* 10:29-39.
- Tipper, D.J. & M.J. Schmitt (1991).** Yeasrt dsRNA viruses: replication and killer phenotypes. *Mol. Microbiol.* 5:2331-2338.
- Troillet, N., Durussel, C., Bille, J., Glauser, M.P. & J.P. Chave (1993).** Correlation between in vitro susceptibility of *Candida albicans* and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients. *J. Clin. Microbiol. Infect. Dis.* 12:911-915.
- Walker, G.M., McLeod, A.H. & V.J. Hodgson (1995).** Interactions between killer yeasts and pathogenic fungi. *FEMS Microbiol. Lett.* 127:213-222.
- Wickner, R.B. (1993).** Double-stranded RNA virus replication and packaging. *J. Biol. Chem.* 268:3797-3800.
- Wingard, J.R. (1995).** Importance of *Candida* species other than *C. albicans* as pathogens in oncology patients. *Clin. Infect. Dis.* 20:115-125.

- 37 -

We claim:

1. A protein toxin which can be obtained from *Williopsis californica* and/or *Zygosaccharomyces bailii*.
- 5 2. A protein toxin as claimed in claim 1, which can be obtained from DSM 12864 and/or DSM 12865 .
3. A protein toxin as claimed in claims 1 and 2, which has an antimycotic and/or fungicidal action.
- 10 4. A protein toxin as claimed in any of claims 1 to 3 with glucanase activity.
- 15 5. A protein toxin as claimed in claim 4, which binds to β -1,6-D-glucans and has β -1,3-D-glucanase and/or β -1,3-glucanosyl transferase activity.
- 20 6. Nucleic acid encoding a glucanase and/or a protein toxin as claimed in any of claims 1-5 with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 8 nucleotides, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.
- 25 7. A nucleic acid as claimed in claim 6, wherein the nucleic acid is a DNA or RNA, preferably a double-stranded DNA.
8. A nucleic acid as claimed in claim 6 or 7, which is a DNA with a nucleic acid sequence in accordance with **SEQ ID No 1** of base position 1 to 951 or **SEQ ID No 2** of base position 1 to 717, where **SEQ ID No 1** or **SEQ ID No 2** is part of the claim.
- 30 9. A nucleic acid as claimed in claim 8, which contains one or more regulatory regions (promoter, enhancer, terminator) and/or a 3'-terminal poly-A sequence and/or a Kex2p endopeptidase cleavage site which is necessary for the intracellular protoxin processing and/or one or more potential N-glycosylation sites.
- 35

10. A nucleic acid as claimed in any of claims 8-9 which can be obtained from DSM 12864 and/or DSM 12865.
- 5 11. A nucleic acid as claimed in any of claims 6-10, which is contained in a vector, preferably in an expression vector or in a vector which is effective in gene therapy.
- 10 12. A process for the preparation of a nucleic acid as claimed in any of claims 6-10, wherein the nucleic acid is synthesized chemically or isolated from a gene library with the aid of a probe.
- 15 13. A polypeptide with an amino acid sequence in accordance with **SEQ ID No 1** or **SEQ ID No 2** or a functional variant thereof, and portions thereof with at least 6 amino acids.
- 20 14. A process for the preparation of a polypeptide as claimed in claims 1-5 and 13, wherein a nucleic acid as claimed in any of claims 6-11 is expressed in a suitable host cell.
- 25 15. An antibody against a polypeptide as claimed in any of claims 1-5 and 13.
- 30 16. A process for the preparation of an antibody as claimed in claim 15, wherein a mammal is immunized with a polypeptide as claimed in claim 7 and, if appropriate, the antibodies formed are isolated.
- 35 17. A drug product comprising a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 and, if appropriate, pharmaceutically acceptable additives and/or adjuvants.
18. A process for the preparation of a drug product for the treatment of mycoses such as superficial, cutaneous and subcutaneous dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably *Candida* mycoses, wherein a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 is/are

formulated together with a pharmaceutically acceptable additive and/or adjuvant.

- 5 19. A diagnostic comprising a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 and, if appropriate, suitable additives and/or adjuvants.
- 10 20. A process for the preparation of a diagnostic for diagnosing mycoses such as superficial, cutaneous and subcutaneous dermatomycoses, mycoses of the mucous membranes and systemic mycoses, especially preferably *Candida* mycoses, wherein a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 is/are combined
15 with a pharmaceutically acceptable carrier.
- 20 21. An assay for identifying functional interactors comprising a nucleic acid as claimed in any of claims 6-10 or a polypeptide as claimed in any of claims 1-5 and 13 or antibodies as claimed in claim 15 and, if appropriate, suitable additives and/or adjuvants.
- 25 22. The use of a nucleic acid as claimed in any of claims 6-10 or of a polypeptide as claimed in any of claims 1-5 and 13 for identifying functional interactors.
- 30 23. The use of a nucleic acid as claimed in any of claims 6-10 for finding variants, which comprises screening a gene library with the abovementioned nucleic acid and isolating the variant which has been found.
- 35 24. The use of a polypeptide as claimed in any of claims 1-5 and 13 for controlling harmful yeasts and fungi in foods and animal feeds.
25. A process for growing DSM 12864 and DSM 12865, which comprises growing them in synthetic B and/or BAVC medium.
26. The use of the nucleic acids as claimed in any of claims 6-11 for the generation of transgenic plants and plant cells.

1999/F028

Novel antimycotics and fungicides, processes for their preparation, and use

Abstract of the disclosure

The invention relates to the recombinant provision of protein toxins from yeasts - so-called killer yeasts - for controlling yeasts and/or fungi which are pathogenic for man and plants, the yeasts and/or fungi being killed selectively. The high specificity allows the use of the protein toxins as antimycotics and/or fungicides. Moreover, such protein toxins can be employed in crop protection.


Fig. 1

WICALTIN: NH₂-Ile-Gly-**Gln**-Leu-Ala-Phe-Asn-Leu-Gly-Val-.....

Bgl2: NH₂-Ile-Gly-**Glu**-Leu-Ala-Phe-Asn-Leu-Gly-Val-.....

Fig. 2

2a)



2b)




Fig. 3





Fig. 4

(A) SDS-PAGE of Zygotin before and after affinity chromatography on mannoprotein-Sepharose. Zygotin was purified on a mannoprotein matrix. [1: LMW marker (Bio-Rad); 2: elute (proteins not bound to matrix); 3: eluted toxin]

(B) MBA test with Zygotin purified by affinity chromatography. *S. cerevisiae* 192.2d was used as the sensitive organism. A: eluate, 15-fold concentration; B: eluate, dialyzed; C: eluate, in elution buffer

Fig. 5




Fig. 6:(A)

Fig. 6




Fig. 1





Fig. 8



WO 01/02587

PCT/EP00/04972

Fig. 9





Fig. 10



COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney Docket No.

99at07.us (8602*37)

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "Novel Antimycotics and Fungicides, Processes for Their Preparation and Their Use"

the specification of which

(check one) ☐ is attached hereto.

☒ was filed on January 3, 2002 as

Application Serial No. 10/019963 and

was amended on January 3, 2002
(if applicable)

was amended through _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or (f) or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's or plant breeder's rights certificate, or PCT International application having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
<u>199 30 959.0</u>	<u>Germany</u>	<u>05/07/1999</u>	<input checked="" type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u>PCT/EP00/04972</u>	<u>International</u>	<u>31/05/2000</u>	<input checked="" type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
_____	_____	_____	<input type="checkbox"/> <input type="checkbox"/>	
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
_____	_____	_____
(Application Serial No.)	(Filing Date)	(Status)
		(patented, pending, abandoned)

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

_____	_____
(Application No.)	(Filing Date)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) associated with CUSTOMER NUMBER 23416, all of CONNOLLY BOVE LODGE & HUTZ LLP, as attorneys with full power of substitution to prosecute this application and conduct all business in the Patent and Trademark Office connected therewith.

Send Correspondence To: Connolly Bove Lodge & Hutz LLP P.O. Box 2207 Wilmington, Delaware 19899-2207		Direct Telephone Calls To: (302) 658-9141	
--	--	--	--

FULL NAME OF SOLE OR FIRST INVENTOR Klaus Rehfeldt	INVENTOR'S SIGNATURE 	DATE 01.03.2002
RESIDENCE Kohlberger Strasse 16a, 76139 Karlsruhe, Germany DEX	CITIZENSHIP Germany	
POST OFFICE ADDRESS Same		
FULL NAME OF SECOND JOINT INVENTOR IF ANY Simone Theisen	INVENTOR'S SIGNATURE 	DATE 06.03.2002
RESIDENCE Kreuzackerstrasse 29, 70794 Eilderstadt-Bonlanden, Germany DEX	CITIZENSHIP Germany	
POST OFFICE ADDRESS Same		
FULL NAME OF THIRD JOINT INVENTOR IF ANY Frank Weiler	INVENTOR'S SIGNATURE 	DATE 02/24/2002
RESIDENCE Bayernstrasse 18, 66111 Saarbrücken, Germany DEX	CITIZENSHIP Germany	
POST OFFICE ADDRESS Same		
FULL NAME OF FOURTH JOINT INVENTOR IF ANY Manfred Schmitt	INVENTOR'S SIGNATURE 	DATE 02/24/2002
RESIDENCE In den Kastler Rödern 14, 66386 St. Ingbert, Germany DEX	CITIZENSHIP Germany	
POST OFFICE ADDRESS Same		
FULL NAME OF FIFTH JOINT INVENTOR IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SIXTH JOINT INVENTOR IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF SEVENTH JOINT INVENTOR IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		
FULL NAME OF EIGHTH JOINT INVENTOR IF ANY	INVENTOR'S SIGNATURE	DATE
RESIDENCE	CITIZENSHIP	
POST OFFICE ADDRESS		

:::ODMA\HODMA\CB;187352,1

WO 01/02587

PCT/EP00/04972

SEQUENCE LISTING

<110> Aventis Research & Technologies GmbH & Co KG

<120> Novel antimycotics and fungicides, process for their preparation, and use

<130> 99F026

<140> 19930959.0

<141> 1999-07-05

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 930

<212> DNA

<213> Williopsis californica

<220>

<221> CDS

<222> (1)..(930)

<400> 1

atg	cgt	ttc	act	aca	ctc	ggt	gcc	ctc	gca	ggt	gcc	att	tcc	tca	gtc	48
Met	Arg	Phe	Thr	Thr	Leu	Val	Ala	Leu	Ala	Gly	Ala	Ile	Ser	Ser	Val	
1				5					10					15		

cag	gcc	atc	ggc	caa	cta	gct	ttt	aac	tct	ggt	gtc	aag	gat	aac	tca	96
Gln	Ala	Ile	Gly	Gln	Leu	Ala	Phe	Asn	Leu	Gly	Val	Lys	Asp	Asn	Ser	
			20				25						30			

ggt	cag	tgc	aag	act	gcc	tca	gag	tac	aag	gat	gac	tgt	tct	acc	ctt	144
Gly	Gln	Cys	Lys	Thr	Ala	Ser	Glu	Tyr	Lys	Asp	Asp	Leu	Ser	Thr	Leu	
		35					40					45				

tca	ggc	tac	aca	tct	aag	gtt	aga	gtc	tac	gct	gcc	tca	gac	tgt	aac	192
Ser	Gly	Tyr	Thr	Ser	Lys	Val	Arg	Val	Tyr	Ala	Ala	Ser	Asp	Cys	Asn	
		50				55					60					

act	tgt	cag	act	tgt	ggt	cca	gtt	gtc	gaa	gag	gct	ggc	ttc	tca	ttt	240
Thr	Leu	Gln	Thr	Leu	Gly	Pro	Val	Val	Glu	Glu	Ala	Gly	Phe	Ser	Phe	
	65				70				75				80			

ttc	gtt	ggt	att	tgg	cca	aac	gat	gat	gct	cac	ttc	cag	gaa	gag	caa	288
Phe	Val	Gly	Ile	Trp	Pro	Asn	Asp	Asp	Ala	His	Phe	Gln	Glu	Glu	Gln	

85	90	95	
gac gct ttg aaa act tat ttg cca aag att aaq aga tcc aca gtg gag			336
Asp Ala Leu Lys Thr Tyr Leu Pro Lys Ile Lys Arg Ser Thr Val Glu			
100	105	110	
gcc ttc act gtt ggt tct gag gcc ttg tat aga gat gat atg act gct			384
Ala Phe Thr Val Gly Ser Glu Ala Leu Tyr Arg Asp Asp Met Thr Ala			
115	120	125	
caa gag ttg gct gac aga atc aaa act att aga gag ttg gct gcc act			432
Gln Glu Leu Ala Asp Arg Ile Lys Thr Ile Arg Glu Leu Val Ala Thr			
130	135	140	
att gac gac tcc gaa ggt aac tca tat gct ggt att cca gtt ggt ttc			480
Ile Asp Asp Ser Glu Gly Asn Ser Tyr Ala Gly ile Pro Val Gly Phe			
145	150	155	160
gtt gac tcc tgg aac gtt ttg gtt gat ggt gct tct cac cca gct att			528
Val Asp Ser Trp Asn Val Leu Val Asp Gly Ala Ser His Pro Ala Ile			
165	170	175	
gtt gag gct gat gtt gtg ttc gcc aat gct ttc tct tac tgg caa ggt			576
Val Glu Ala Asp Val Val Phe Ala Asn Ala Phe Ser Tyr Trp Gln Gly			
180	185	190	
cag act cag cag aac tcg tca tac tct ttc ttt gac gac att atg caa			624
Gln Thr Gln Gln Asn Ser Ser Tyr Ser Phe Phe Asp Asp Ile Met Gln			
195	200	205	
gct ttg caa acc att caa act gct aag ggt gag aca gat atc act ttc			672
Ala Leu Gln Thr Ile Gln Thr Ala Lys Gly Glu Thr Asp Ile Thr Phe			
210	215	220	
tgg gtt ggt gag acc ggc tgg cca acc gat ggt act cac ttt gaa gac			720
Trp Val Gly Glu Thr Gly Trp Pro Thr Asp Gly Thr His Phe Glu Asp			
225	230	235	240
tct gtc cca tct gtt gag aat gct cag acc ttc tgg aaa gat gcc gtc			768
Ser Val Pro Ser Val Glu Asn Ala Gln Thr Phe Trp Lys Asp Ala Val			
245	250	255	
tgt gcc att aga ggt tgg ggt atc aat gtt att gcc ttt gag gcc ttt			816
Cys Ala Ile Arg Gly Trp Gly Ile Asn Val Ile Ala Phe Glu Ala Phe			
260	265	270	
gac gaa gct tgg aag cca gat acc tct ggt acc tct gat gtg gaa aag			864
Asp Glu Ala Trp Lys Pro Asp Thr Ser Gly Thr Ser Asp Val Glu Lys			

WO 01/02587

PCT/EP00/04972

275 280 285
 tac tgg ggt gtt tgg gac tct aac agc aag ttg aag tat gat ttg tcc 912
 Tyr Trp Gly Val Trp Asp Ser Asn Ser Lys Leu Lys Tyr Asp Leu Ser
 290 295 300
 tgt gac ttt acc tct tag 930
 Cys Asp Phe Thr Ser
 305 310

<210> 2
 <211> 309
 <212> .PRT
 <213> Williopsis californica

<400> 2
 Met Arg Phe Thr Thr Leu Val Ala Leu Ala Gly Ala Ile Ser Ser Val
 1 5 10 15
 Gln Ala Ile Gly Gln Leu Ala Phe Asn Leu Gly Val Lys Asp Asn Ser
 20 25 30
 Gly Gln Cys Lys Thr Ala Ser Glu Tyr Lys Asp Asp Leu Ser Thr Leu
 35 40 45
 Ser Gly Tyr Thr Ser Lys Val Arg Val Tyr Ala Ala Ser Asp Cys Asn
 50 55 60
 Thr Leu Gln Thr Leu Gly Pro Val Val Glu Glu Ala Gly Phe Ser Phe
 65 70 75 80
 Phe Val Gly Ile Trp Pro Asn Asp Asp Ala His Phe Gln Glu Glu Gln
 85 90 95
 Asp Ala Leu Lys Thr Tyr Leu Pro Lys Ile Lys Arg Ser Thr Val Glu
 100 105 110
 Ala Phe Thr Val Gly Ser Glu Ala Leu Tyr Arg Asp Asp Met Thr Ala
 115 120 125
 Gln Glu Leu Ala Asp Arg Ile Lys Thr Ile Arg Glu Leu Val Ala Thr
 130 135 140
 Ile Asp Asp Ser Glu Gly Asn Ser Tyr Ala Gly Ile Pro Val Gly Phe
 145 150 155 160
 Val Asp Ser Trp Asn Val Leu Val Asp Gly Ala Ser His Pro Ala Ile

WO 01/02587

PCT/EP00/04972

165 170 175
Val Glu Ala Asp Val Val Phe Ala Asn Ala Phe Ser Tyr Trp Gln Gly
180 185 190
Gln Thr Gln Gln Asn Ser Ser Tyr Ser Phe Phe Asp Asp Ile Met Gln
195 200 205
Ala Leu Gln Thr Ile Gln Thr Ala Lys Gly Glu Thr Asp Ile Thr Phe
210 215 220
Trp Val Gly Glu Thr Gly Trp Pro Thr Asp Gly Thr His Phe Glu Asp
225 230 235 240
Ser Val Pro Ser Val Glu Asn Ala Gln Thr Phe Trp Lys Asp Ala Val
245 250 255
Cys Ala Ile Arg Gly Trp Gly Ile Asn Val Ile Ala Phe Glu Ala Phe
260 265 270
Asp Glu Ala Trp Lys Pro Asp Thr Ser Gly Thr Ser Asp Val Glu Lys
275 280 285
Tyr Trp Gly Val Trp Asp Ser Asn Ser Lys Leu Lys Tyr Asp Leu Ser
290 295 300
Cys Asp Phe Thr Ser
305

<210> 3
<211> 717
<212> DNA
<213> Zygosaccharomyces bailii

<220>
<221> CDS
<222> (1)..(717)

<400> 3
atg aaa gca gcc caa ata tta aca gca agt ata gta agc tta ttg cca 48
Met Lys Ala Ala Gln Ile Leu Thr Ala Ser Ile Val Ser Leu Leu Pro
1 5 10 15
ata tat act agt gct aga aac ata tta gac aga gaa tac aca gca aac 96
Ile Tyr Thr Ser Ala Arg Asn Ile Leu Asp Arg Glu Tyr Thr Ala Asn
20 25 30


```

gaa tta aaa act gct ttt gga gat gaa gaa att ttt aca gat ttg acg      144
Glu Leu Lys Thr Ala Phe Gly Asp Glu Glu Ile Phe Thr Asp Leu Thr
      35                      40                      45

tat cac att cac gtt aac gtc agt ggc gaa att gac tct tac tat cat      192
Tyr His Ile His Val Asn Val Ser Gly Glu Ile Asp Ser Tyr Tyr His
      50                      55                      60

aat tta gtc aat ttt gtc gat aac gct cta gca aac aaa gat att aat      240
Asn Leu Val Asn Phe Val Asp Asn Ala Leu Ala Asn Lys Asp Ile Asn
      65                      70                      75                      80

aga tat ata tac gct ata ttt aca cag cag aca aac tat aca gag gat      288
Arg Tyr Ile Tyr Ala Ile Phe Thr Gln Gln Thr Asn Tyr Thr Glu Asp
      85                      90                      95

ggg ctc att gag tac tta aat cat tac gat tca gag act tgc aaa gat      336
Gly Leu Ile Glu Tyr Leu Asn His Tyr Asp Ser Glu Thr Cys Lys Asp
      100                      105                      110

atc att act cag tat aat gtt aac gta gac act agt aac tgt ata agc      384
Ile Ile Thr Gln Tyr Asn Val Asn Val Asp Thr Ser Asn Cys Ile Ser
      115                      120                      125

aat act aca gat caa gct aga ctc caa cgt cgc gga ggg tgg gtg aac      432
Asn Thr Thr Asp Gln Ala Arg Leu Gln Arg Arg Gly Gly Trp Val Asn
      130                      135                      140

cca cat tgt agt ggt gat aac tta gcc gat act agc gat tgt tgt aac      480
Pro His Cys Ser Gly Asp Asn Leu Ala Asp Thr Ser Asp Cys Cys Asn
      145                      150                      155                      160

ttg gct tat aac aag att aac ccc tct tca aac tta cag tca tgg aat      528
Leu Ala Tyr Asn Lys Ile Asn Pro Ser Ser Asn Leu Gln Ser Trp Asn
      165                      170                      175

tat gtt gtc ggg cag tgt cac tat att tct cac gct aat gga aag gta      576
Tyr Val Val Gly Gln Cys His Tyr Ile Ser His Ala Asn Gly Lys Val
      180                      185                      190

tgt agt ggt gct gac agg caa cag tta gct gaa aat gta tgt aac tgg      624
Cys Ser Gly Ala Asp Arg Gln Gln Leu Ala Glu Asn Val Cys Asn Trp
      195                      200                      205

tgt cag gtt aac ggt ggt gtt agc gct ttt gct agc agt agt tct gca      672
Cys Gln Val Asn Gly Gly Val Ser Ala Phe Ala Ser Ser Ser Ser Ala
      210                      215                      220

```

WO 01/02587

PCT/EP00/04972

cat cca ggt gct tgc atg agt gat gta ggg ttc tgc tat gct tag 717
His Pro Gly Ala Cys Met Ser Asp Val Gly Phe Cys Tyr Ala
225 230 235

<210> 4
<211> 238
<212> PRT
<213> Zygosaccharomyces bailii

<400> 4
Met Lys Ala Ala Gln Ile Leu Thr Ala Ser Ile Val Ser Leu Leu Pro
1 5 10 15
Ile Tyr Thr Ser Ala Arg Asn Ile Leu Asp Arg Glu Tyr Thr Ala Asn
20 25 30
Glu Leu Lys Thr Ala Phe Gly Asp Glu Glu Ile Phe Thr Asp Leu Thr
35 40 45
Tyr His Ile His Val Asn Val Ser Gly Glu Ile Asp Ser Tyr Tyr His
50 55 60
Asn Leu Val Asn Phe Val Asp Asn Ala Leu Ala Asn Lys Asp Ile Asn
65 70 75 80
Arg Tyr Ile Tyr Ala Ile Phe Thr Gln Gln Thr Asn Tyr Thr Glu Asp
85 90 95
Gly Leu Ile Glu Tyr Leu Asn His Tyr Asp Ser Glu Thr Cys Lys Asp
100 105 110
Ile Ile Thr Gln Tyr Asn Val Asn Val Asp Thr Ser Asn Cys Ile Ser
115 120 125
Asn Thr Thr Asp Gln Ala Arg Leu Gln Arg Arg Gly Gly Trp Val Asn
130 135 140
Pro His Cys Ser Gly Asp Asn Leu Ala Asp Thr Ser Asp Cys Cys Asn
145 150 155 160
Leu Ala Tyr Asn Lys Ile Asn Pro Ser Ser Asn Leu Gln Ser Trp Asn
165 170 175
Tyr Val Val Gly Gln Cys His Tyr Ile Ser His Ala Asn Gly Lys Val
180 185 190

WO 01/02587

PCT/EP00/04972

Cys Ser Gly Ala Asp Arg Gln Gln Leu Ala Glu Asn Val Cys Asn Trp
195 200 205

Cys Gln Val Asn Gly Gly Val Ser Ala Phe Ala Ser Ser Ser Ser Ala
210 215 220

His Pro Gly Ala Cys Met Ser Asp Val Gly Phe Cys Tyr Ala
225 230 235